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ABSTRACT OF DISSERTATION 
 
 
PROTEIN KINASE A AND EPAC MEDIATE CHRONIC PAIN AFTER INJURY: 
PROLONGED INHIBITION BY ENDOGENOUS Y1 RECEPTORS IN DORSAL HORN 
  
 Inflammation or nerve injury sensitizes several populations of nociceptive neurons in 
the dorsal horn of the spinal cord, including those that express the neuropeptide Y (NPY) 
Y1 receptor (Y1R). Our overall hypothesis is that after tissue or nerve injury, these Y1R-
expressing neurons enter a state of latent sensitization (LS) that contributes to 
vulnerability to the development of chronic pain; furthermore, LS is under the tonic 
inhibitory control of endogenous Y1R signaling. First, we evaluated the intracellular 
signaling pathways that become activated in Y1R-expressing neurons and participate in 
LS. To do this, we established behavioral models of inflammatory or neuropathic pain, 
allowed pain hypersensitivity to resolve, and then during this period of pain remission we 
administered the Y1R receptor antagonist, BIBO3304, by intrathecal injection. As 
observed previously with mu-opioid receptor antagonists/inverse agonists, we found that 
BIBO3304 reinstated pain hypersensitivity via an N-methyl-D-aspartate receptor 
(NMDAR)- and adenylyl cyclase type 1 (AC1)-dependent mechanism. Our subsequent 
behavioral pharmacological experiments then established two signaling pathways 
downstream of AC1 that maintain LS. The first pathway involves protein kinase A (PKA) 
and transient receptor potential cation channel A1 (TRPA1) and channel V1 (TRPV1). The 
second pathway involves exchange proteins activated by cAMP (Epac 1 and Epac 2). We 
next found that nerve injury decreases the co-expression of Y1R with markers of excitatory 
interneurons, suggesting that Y1R-expressing neurons acquire a pain-enhancing 
phenotype after peripheral nerve injury. In a separate set of experiments that utilized Y1R-
receptor internalization as an index of NPY release, we found that nerve injury increased 
stimulus-evoked NPY release. We conclude that injury induces pain-facilitatory 
mechanisms of LS in the dorsal horn involving PKATRPA1 and PKATRPV1 at the 
central terminals of primary afferent neurons. Whether Epac mechanisms are located on 
these same presynaptic terminals and/or at Y1R-expressing excitatory interneurons 
remain to be determined. We also conclude that injury-induced LS is masked by a 
compensatory up-regulation of spinal NPY release that tonically inhibits pain. These 
results present a novel mechanism of injury-induced LS and endogenous control of the 
transition from acute to chronic pain by the NPY-Y1R system. Our work sheds light on 
novel targets for the treatment of chronic pain.  
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CHAPTER 1:   Background 
 
1.1  Overall hypothesis and specific aims 
 My central hypotheses are: (i) after tissue or nerve injury, Y1R-expressing neurons 
enter a state of latent sensitization (LS) that contributes to vulnerability to the development 
of chronic pain; (ii) LS is under the tonic inhibitory control of endogenous NPY-Y1R axis; 
and (iii) LS is driven by a PKA/Epac-dependent mechanism. To test these hypotheses, I 
designed and performed experiments to investigate the following specific aims:  
1) Test whether NPY-Y1R-inhibited LS is driven by the NMDAR-AC1-PKA-
TRPA1/TRPV1 signaling pathway. 
2) Test whether NPY-Y1R-inhibited LS is driven by the NMDAR-AC1-Epac signaling 
pathway. 
3) Determine whether Y1R is exclusively expressed on neurons in the dorsal horn, 
before and after inflammation or nerve injury.   
4) Determine what population of primary afferent terminals has Y1R in the superficial 
lamina of dorsal horn.  
5) Determine what subpopulation of spinal interneurons express Y1R in the 
superficial lamina of dorsal horn, and whether injury changes this phenotype. 
6) Develop a new in situ assay to measure spinal NPY release by quantification of 
Y1R internalization. Use this assay to determine whether spinal NPY release is 
increased after injury. 
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1.2  Pain 
1.2.1  Pain: definition and classification  
 “Pain, like love, is all consuming: when you have it, not much else matters, and there 
is nothing you can do about it.” (Woolf 2010) 
                                                                                                                ---Clifford J. Woolf  
According to the International Association for the Study of Pain (IASP), pain is defined 
as “an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage”. Both physiological (sensory) and 
psychological (emotional) components are involved in pain by this definition, mediated by 
somatosensory and limbic systems, respectively. This research will focus on the sensory 
aspect of pain, assessed using reflexive tests, such as vonFrey filaments, or acetone cold 
testing. These tests typically measure the latency to withdraw an extremity from a noxious 
stimulus. 
Pain can be roughly classified into three categories: Acute, inflammatory, and 
neuropathic pain. Acute or nociceptive pain is a high-threshold pain that protects an 
organism from harmful and threatening stimuli. People who have congenital insensitivity 
to pain are incapable of nociception, and usually suffer from extensive tissue damage and 
decreased lifespan. Inflammatory pain is caused by tissue damage or inflammation, and 
is associated with activation of the innate immune system (Woolf 2010). By contrast, 
neuropathic pain is “initiated or caused by a primary lesion or dysfunction in the nervous 
system” (IASP). Both inflammatory and neuropathic injuries can lead to chronic pain 
conditions. Chronic pain “persists past the normal time of healing” (Bonica 1953). This 
length of time is determined subjectively, by medical experience, and differs for various 
chronic pain syndromes (IASP). Chronic pain serves no benefit and can dramatically 
decrease quality of life. It incurs a medical, societal, and financial burden, and 
detrimentally disrupts physiological and psychological functioning and productivity. The 
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Institute of Medicine states that 100 million Americans are burdened with chronic pain, 
which costs up to $635 billion dollars annually (IOM 2016). 
Chronic pain is largely refractory to currently available analgesic drugs, which produce 
numerous undesirable effects including dependence, abuse liability, constipation and 
nausea. Thus, the search for novel drug targets is a primary challenge in chronic pain 
research. Developing novel drug targets relies on a better understanding of the 
mechanisms by which the endogenous inhibitory systems impede the transition from acute 
to chronic pain.  A major goal of this dissertation is to propose novel therapeutic targets 
for chronic pain management.  
 
1.2.2  Nociceptive circuitry  
1.2.2.1  Peripheral sensory fibers 
Primary afferent nociceptors are peripheral sensory neurons that detect noxious 
mechanical, thermal, and chemical stimuli from the periphery, and conduct the 
nociceptive information to the spinal cord. They are pseudo-unipolar cell bodies residing 
in the dorsal root ganglia (DRG) or trigeminal ganglia (TG). Distal branches of their 
axons innervate the peripheral tissue or organ, and central branches of their axons 
innervate the spinal cord. There are two major types of nociceptors, C- and Aδ-fibers. C-
fibers are unmyelinated, small diameter, slow conducting fibers that convey slow and 
diffuse pain, while Aδ-fibers are thinly-myelinated, medium size, faster conducting fibers 
that mediate fast and well-localized pain. Both C- and Aδ-fibers are heterogeneous. C-
fibers can be further classified into peptidergic and non-peptidergic populations. The 
former contain and release neuropeptides, such as calcitonin-gene related peptide 
(CGRP) and substance P (SP), and the latter contain isolectin IB4.  
In pathological conditions, another type of primary afferent fibers might also be 
recruited to convey noxious information, the Aβ-fibers. They are large, thickly-
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myelinated, fastest conducting sensory fibers which convey innocuous tactile information 
in the physiological condition (Basbaum et al. 2009). 
 
1.2.2.2  Anatomical arrangement of dorsal horn and spinal innervation of primary afferent 
terminals  
The dorsal horn of the spinal cord can be divided into Laminae I-VI (Rexed 1954). 
Laminae I and II are considered superficial dorsal horn, also known as the “substantia 
gelatinosa”. As shown in Figure 1-1, peptidergic C-fibers project to Laminae I and outer 
II, whereas non-peptidergic populations project to inner Lamina II, indicating functional 
differences between these populations. Aδ-fibers project to lamina I and deeper lamina 
V. Aβ-fibers project to deeper laminae III- V; it is notable that this includes the band of 
protein kinase C gamma (PKCγ)- positive interneuron that demarcates the border 
between inner lamina II and outer lamina III (Basbaum et al. 2009, Braz et al. 2014).  
Three branches of the sciatic nerve project to lumbar segments (L4-L6 for rats; L3-L5 
for mice) of the spinal cord. As illustrated in Figure 1-2, these branches consist of the 
tibial, common peroneal, and sural nerves. They retain somatotopic organization in the 
innervation zones, with the tibial nerve terminating in the middle zone, the common 
peroneal nerve terminating in the medial-central zone, and the sural nerve terminating in 
the central-lateral zone of the spinal cord (Corder et al. 2010).  
The dorsal horn is an integrative center that processes and modulates noxious 
information. After receiving direct and indirect nociceptive inputs from  the central 
terminals of primary afferent neurons, projection neurons located in Lamina I [80% 
neurokinin 1 (NK1)- positive (Todd et al. 2002)] and III-V transmit noxious information to 
the brain for further processing, leading to the perception of pain. 
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Figure 1-1. Dorsal spinal laminar organization and inputs from primary afferent 
fibers 
[Adapted from (Basbaum et al. 2009)] 
Lamina I projection neurons receive inputs from the unmyelinated peptidergic C and 
thinly myelinated Aδ nociceptors. Outer lamina II interneurons receive inputs from Aδ 
nociceptors. Dorsal inner lamina II interneurons receive inputs from unmyelinated non-
peptidergic C nociceptors. Ventral inner lamina II interneurons (PKCγ+) receive inputs 
from thickly myelinated Aβ fibers. Lamina V projection neurons receive convergent 
inputs from Aδ and Aβ fibers. 
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Figure 1-2. Periphery and central innervation sites of sciatic nerves 
 [Adapted from (Corder et al. 2010)] 
The termination sites of the three primary distal branches of the sciatic nerve, sural, 
tibial, and common peroneal at the level of planter and L4 spinal cord. M, medial; MC, 
medial-central; and CL, central-lateral zones of the superficial dorsal horn of dorsal horn. 
1.2.2.3  Supraspinal processing and modulation 
The ascending noxious information conveyed from superficial dorsal horn is further 
conducted to somatosensory cortex relayed through thalamus, encoding the sensory 
features of pain, or conducted to insular cortex and cingulate cortex through brain stem 
and amygdala, contributing to the affective aspect of pain (Basbaum et al. 2009, Ossipov 
et al. 2014). The periaqueductal gray (PAG) and rostroventromedial medulla (RVM) 
receive ascending nociceptive input through spinothalamic collateral innervation, and 
descending information from higher brain regions to further modulate pain (Ossipov et al. 
2014). In this dissertation, we will spotlight spinal mechanisms of pain transmission and 
modulation.   
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1.2.3  Spinal nociceptive plasticity  
IASP describes central sensitization (CS) as increased responsiveness of CNS 
nociceptive neurons to normal or subthreshold afferent input. CS of spinal dorsal neurons 
can be induced by tissue injury, periphery inflammation, or even dysfunction of the 
endogenous inhibitory control systems. It is an activity-dependent phenomenon that 
requires the activity of N-Methyl-D-aspartate receptors (NMDAR). Long-term potentiation 
(LTP) of spinal neurons may be one of the mechanisms underlying CS (Sandkuhler 2007, 
Latremoliere et al. 2009). 
CS contributes to the persistent pain conditions after inflammation or nerve injury 
(Latremoliere et al. 2009). However, even after the restoration of pain thresholds, animals 
may still exhibit long-lasting pain vulnerability, referred to as latent sensitization (LS). For 
example, with subsequent injury or stressors, they become more susceptible to intense 
allodynia or hyperalgesia (Figure 1-3) (Taylor et al. 2014). Behavioral manifestations of 
LS occur after mustard oil-induced hyperalgesia (Yu et al. 1994), opioid-induced 
hyperalgesia (Laulin et al. 1998, Lian et al. 2010), skin incision (Campillo et al. 2011, 
Corder et al. 2013), intraperitoneal carrageenan (Rivat et al. 2007), intraperitoneal CFA 
(Solway et al. 2011, Corder et al. 2013), and peripheral nerve injury (Solway et al. 2011, 
Corder et al. 2013).  The animal models of LS is powerful, broad range, and repeatable 
(Solway et al. 2007 , Corder et al. 2013).  
LS could contribute to the mechanism responsible for the transition from acute to 
chronic pain (Solway et al. 2011, Corder et al. 2013), and is found in humans (Pereira et 
al. 2015), highlighting its clinical importance. However, the cellular and molecular 
mechanism of LS remains largely unknown. In Chapter 2 and 3, we describe studies which 
sought to identify a molecular signaling pathway that drives LS in the spinal level after 
injury, and investigate how these pathways can be controlled by the endogenous NPY 
system. 
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Figure 1-3. General model of masking the latent sensitization by NPY signaling 
after injury. 
[Adapted from (Solway et al. 2011) and (Taylor et al. 2014)] 
Injury triggers a sustained neuronal sensitization (LS, Green line). A compensatory NPY 
Y1R analgesia (NPY, Blue line) silences LS and thus enables the resolution of pain (red 
line). If this balance is perturbed, for example, upon blockade of Y1R (dotted line), then 
LS can be visualized as pain reinstatement.  
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1.2.4  Spinal pain mediators 
1.2.4.1  NMDAR 
The NMDAR is a non-selective cation channel (permeable to both Na+ and Ca2+) 
which can be found in almost every synapse in the superficial dorsal horn. Under resting 
conditions, the NMDAR is blocked by a magnesium ion (Mg2+) sitting in its pore; membrane 
depolarization can lead to Mg2+ exiting the pore; upon glutamate binding, an influx of Ca2+ 
triggers protein phosphorylation and downstream signaling cascades, ultimately leading 
to the induction and, with continued activation, maintenance of  CS [See review 
(Latremoliere et al. 2009)]. The NMDAR is considered not only a trigger, but also an 
effector of CS, because blockade of NMDARs with its antagonist MK801 or DCPP 
abolishes the hyper-excitability of nociceptive neurons induced by noxious input.  
 
1.2.4.2  Adenylyl cyclase type 1 (AC1) 
Adenylyl cyclases (ACs) are membrane-bound enzymes that catalyzes the conversion 
of ATP to the second messenger, cAMP. AC1 is found in superficial laminae of spinal cord 
and activated by Ca2+/calmodulin following NMDAR activation (Wei et al. 2002). In vitro 
studies performed in spinal cord slices suggest that AC1 contributes to high frequency 
stimulation-induced LTP (Wang et al. 2011). AC1 knockout reduces mechanical 
hypersensitivity following CFA (Wei et al. 2002) and common peroneal nerve ligation (Xu 
et al. 2008). Activation of Gi/o- coupled receptors inhibits ACs; however, prolonged 
activation of the inhibitory G-protein coupled receptors (GPCRs) leads to sensitization of 
AC, often observed as cAMP overshoot upon pharmacological blockade of GPCRs. This 
phenomenon is referred to as “AC superactivation” (Avidor-Reiss et al. 1996).  
Just as Corder et al. described that NMDAR-dependent AC1 superactivation-driven 
LS is under the control of an endogenous spinal µ-opioid receptor signaling system after 
inflammation (Corder et al. 2013), Chapter 2 tests our hypothesis that NMDAR-dependent 
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AC1 superactivation contributes to LS that is under the control of endogenous NPY-Y1R 
signaling not only after inflammation, but also after nerve injury. 
 
1.2.4.3  Protein kinase A (PKA) 
PKA is a well-known cAMP-dependent kinase. The inactive form of PKA is a tetramer 
that contains 2 regulatory and 2 catalytic subunits. cAMP binding to the regulatory subunits 
will cause dissociation of the catalytic subunits, leading to PKA activation. PKA contributes 
to CS by phosphorylating NMDARs and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs), changing the threshold and activation 
kinetics of the receptors, or by inserting of more NMDAR and AMPAR into the cell 
membrane to boost synaptic efficacy [See review (Latremoliere et al. 2009)]. PKA was 
also found to mediate LS in a hyperalgesic priming [a long-lasting latent hyper-
responsiveness of nociceptors to inflammatory mediators following inflammation or nerve 
injury (Aley et al. 2000, Parada et al. 2003, Reichling et al. 2009)]  model induced by 
repeated µ-opioid exposure (Araldi et al. 2015). 
 
1.2.4.4  Exchange protein directly activated by cAMP (Epac) 
Discovered much more recently than PKA, Epac is an alternative cAMP effector 
(Dodge-Kafka et al. 2005, Chen et al. 2013). Epac is a nucleotide exchange factor which 
catalyzes GDP/GTP exchange in small G-proteins (de Rooij et al. 1998, Kawasaki et al. 
1998). Similar to PKA, the activation of Epac also involves cAMP binding and dissociation 
of its regulatory subunit. Two proteins comprise the Epac family in mammals: Epac1 
(RapGef3, cAMP-GEF I) and Epac2 (RapGef4, cAMP-GEF II). An emerging literature 
suggests that they are involved in pain processing through activation of PKC after 
inflammation (Griffin 2005, Hucho et al. 2005, Eijkelkamp et al. 2010, Wang et al. 2013, 
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Gu et al. 2016, Singhmar et al. 2016) and nerve injury (Eijkelkamp et al. 2013). After CFA-
induced inflammation, expression of both Epac1 and Epac2 in DRG is significantly 
increased (Gu et al. 2016). In Chapter 2, we describe the results of experiments designed 
to evaluate the contribution of PKA and Epac to LS. 
 
1.2.4.5  Transient receptor potential cation channel A1 (TRPA1) and V1 (TRPV1) 
Non-selective cation channels TRPA1/V1 are polymodal sensors located on 
nociceptor cell bodies and fibers. They detect somatosensory stimuli and transmit noxious 
information to the spinal cord (Julius 2013). Almost all TRPA1-positive DRG contain 
TRPV1, and about 30% of TRPV1-positive DRG are TRPA1-positive (Story et al. 2003).  
TRPA1 is implicated in many pain conditions (Kwan et al. 2006, Basbaum et al. 2009). 
Phosphorylation by PKA is required for TRPA1 activation or sensitization under several 
pain-related circumstances (Wang et al. 2008, Schmidt et al. 2009, Chen et al. 2011). 
Similarly, phosphorylation of TRPV1 by PKA causes sensitization or reduced 
desensitization of the channel, leading to increased responsiveness of pain-processing 
neurons, or affecting adaptation during pain perception (Lopshire et al. 1998, Bhave et al. 
2002, Rathee et al. 2002, Mohapatra et al. 2003, Mohapatra et al. 2005, Yao et al. 2005). 
Please refer to Chapter 2 for greater details. In Chapter 2, we describe the results of our 
studies that were designed to evaluate the contribution of TRPA1 and TRPV1 to LS. 
 
1.2.5  Specificity vs pattern theory of pain processing   
There has been a long debate as to how noxious mechanical, temperature, and 
chemical inputs are differentially encoded during transmission. The specificity theory, 
supported by the identification of modality-specific nociceptors (Burgess et al. 1967, 
Bessou et al. 1969, Christensen et al. 1970), states that there are “labeled lines” carrying 
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modality-specific information from periphery to the central nervous system (CNS). In 
contrast, pattern theory argues that the brain reads a pattern across multimodal lines of 
activity (Noordenbos 1987). In particular, the Gate Control Theory by Melzak and Wall 
(Melzack et al. 1965, Wall 1978), proposed that the spinal nociceptive 
projection/transmission (T) neurons receive inputs from Aδ/C nociceptors and Aβ 
mechanoreceptors.  Aβ fibers close the gate by feedforward activation of the inhibitory 
interneurons in substantia gelatinosa, while nociceptors open the gate by direct activation 
of the T cells as well as inhibition of the inhibitory interneurons (Figure 1-4). 
Half a century later, a consensus seems to be emerging that both theories are correct 
at a certain level. Labeled lines exist at least at the level of the periphery, with identification 
of distinct populations of nociceptors transmitting modality-specific nociceptive information 
(Julius et al. 2001, Basbaum et al. 2009, Cavanaugh et al. 2009). Although very recent 
studies now suggest that modality-specific transmission exists beyond the peripheral 
nervous system, at the dorsal horn, in the CNS, pattern theory is prevailing. For example, 
two key arguments of Gate Control Theory have been supported (Duan et al. 2014):  
1) Disinhibition could be a mechanism for light touch induced mechanical allodynia   
      (Price et al. 2009, Sandkuhler 2009, Zeilhofer et al. 2012, Prescott et al. 2014). 
2) Poly-synaptic connections of Aβ-fibers from Lamina III to Lamina I projection 
neurons have been confirmed with electrophysiological studies (Baba et al. 2003, 
Torsney et al. 2006, Miraucourt et al. 2007, Lu et al. 2013). 
14 
 
 
 
 
Figure 1-4. The Gate Control Theory of pain 
The modified Gate Control Theory of pain. Activation of nociceptors “opens” the gate; 
while activation of large diameter afferents closes the gate. Recent publication added an 
“E” cell (excitatory interneuron) to the circuity to integrate inputs from periphery sensory 
fibers and “IN” cells (inhibitory interneuron) and relay the nociceptive information to the “T” 
cell (projection neuron) in Lamina I (see Section 1.2.6 for details). Line Arrows denote 
activation; Line Dots denote inhibition. Dash Line Dots denote the proposed inhibition by 
the theory that has not been demonstrated in literature yet.  
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1.2.6  Spinal interneurons process and modulate the inflow and outflow of sensory 
information  
Other than the small population of projection neurons, the vast majority neurons in 
the dorsal horn are interneurons (Chung et al. 1984). They receive inputs and synapse 
locally within the spinal cord. Spinal interneurons can be excitatory or inhibitory. 
Excitatory interneurons are under the control of a group of distinct transcription factors 
during embryonic development, such as T-cell Leukemia homeobox 1 (Tlx1) and Tlx3 
(Xu et al. 2008, Xu et al. 2013, Juarez-Morales et al. 2016). These interneurons 
synthesize glutamate as a primary neurotransmitter and can be identified with the 
expression of vesicular glutamate transporter VGLUT2 (Oliveira et al. 2003, Santos et al. 
2009). Another subset of transcription factors determines the fate of inhibitory 
interneurons by maintaining the level of Pared box gene 2 (Pax2) during early 
development (Glasgow et al. 2005, Pillai et al. 2007). The inhibitory interneurons use 
GABA as a primary neurotransmitter, and thus can be identified with the enzyme 
required for GABA synthesis, glutamic acid decarboxylase (GAD67). Some inhibitory 
interneurons co-express glycine. 
Both excitatory and inhibitory interneurons are extremely heterogeneous. Thus, 
neurochemical markers have been used to define distinct subpopulations of excitatory 
interneurons including PKCγ (Polgar et al. 1999), somatostatin (Todd et al. 2003), and 
calretinin (Smith et al. 2015). Inhibitory interneurons can be categorized based on their 
expression of neuropeptide tyrosine (NPY), neuronal nitric oxide synthases (nNOS), 
galanin, or parvalbumin (Polgar et al. 2011). These neurochemically distinct 
subpopulations of interneurons most likely function differently in the nociceptive circuitry 
(Braz et al. 2014). So far, investigators have gained only limited knowledge about the 
function of these subpopulations. In Chapter 3, we sought to investigate the co-
expression pattern of NPY Y1 receptor (Y1R)-expressing spinal neurons with markers of 
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spinal interneuron subtypes and discuss here and in Chapter 5 their possible roles in the 
context of Gate Control Theory. 
 
1.2.6.1  Somatostatin+ excitatory interneuron 
Most somatostatin-containing boutons contain VGLUT2 (Todd et al. 2003), and 
somatostatin lineage-TdTomato cells are extensively co-labelled with VLGUT2 mRNA 
(Duan et al. 2014). Somatostatin lineage-TdTomato cells are confined mainly in Lamina 
II, and scattered into Laminae I and III-V, with no co-localization with NK1. Thus 
somatostatin-expressing neurons are most likely excitatory interneurons. In addition, 
selective ablation of somatostatin lineage neurons, using an intersectional genetic 
strategy, decreased mechanical hypersensitivity associated with spared nerve injury (SNI) 
in the mouse. Furthermore, electrophysiological studies revealed mono- or poly-synaptic 
inputs from Aβ- fibers to somatostatin-expressing neurons, gated by dynophin- lineage 
inhibitory interneurons (Duan et al. 2014). These data suggest that spinal somatostatin-
positive excitatory interneurons are the “E” cell in my modified model of Gate Control 
Theory (Figure 1-4), relaying the information of mechanical modality of neuropathic pain 
to the “T” cell. In Chapter 3, consistent with literature (Zhang et al. 1999), we found that a 
significant proportion of Y1R-immunoreactive neurons in lamina II contain somatostatin-
like immunoreactivity. 
 
1.2.6.2  Calretinin+ excitatory interneuron 
The permanent calretinin-expressing spinal neurons are confined in outer Lamina II 
(Peirs et al. 2015). They are largely, but not exclusively, restricted to glutamatergic cells 
(Todd 2010). They were proposed to be bridges between VGLUT3 cells which directly 
receive inputs from Aβ-fibers in lamina III and NK1+ projection neurons in Lamina I for 
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mechanical hypersensitivity transmission (Peirs et al. 2015). However, controversy exists 
in literature (Duan et al. 2014). Please refer to Chapter 3 for greater details.  In Chapter 3, 
we describe a subset of Y1R-immunoreactive neurons in lamina II that contain calretinin 
immunoreactivity. 
 
1.2.6.3  NPY+ inhibitory interneuron 
Extensive anatomical evidence has described NPY-expressing spinal interneurons as 
GABAergic (Rowan et al. 1993), and thus inhibitory. NPY+ interneurons constitute 4 – 6% 
of the total neuronal population in laminae I–III. 13 – 15% of GABAergic boutons are NPY 
positive in laminae I–II, and 5% of those are NPY positive in lamina III (Polgar et al. 2011). 
NPY-expressing inhibitory interneurons receive direct inputs from both TRPV1+ (Polgar 
et al. 2013) and TPRV1- (Iwagaki et al. 2016) nociceptors, probably in a species-
dependent manner. NPY+ interneurons form direct synaptic contacts with NK1+ projection 
neurons in Lamina III, PKCγ+ excitatory interneurons in the ventral inner Lamina II, and 
gephyrin-coated lamina I projection cells (Polgar et al. 2011, Polgar et al. 2013). These 
features suggest that NPY+ interneurons are a promising candidate to be the “IN” cell in 
the Gate Control Theory of pain.  
Indeed, a study with intersectional genetic ablation of NPY in dorsal horn neurons, 
suggested that NPY+ interneurons gate mechanical itch (Bourane et al. 2015). Although 
this study failed to find that NPY+ interneurons have a role in acute pain control, this does 
not preclude the possible contribution of NPY-expressing interneurons in the gating of 
chronic pain. Please refer to Chapter 3 for a deeper discussion. 
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1.3  NPY and pain  
1.3.1  NPY and Y1R 
First discovered by Tatemoto et al., (Tatemoto 1982), NPY is a 36-amino acid peptide. 
It is the most abundant peptide in the mammalian CNS, expressed in highest 
concentrations in the arcuate nucleus of the hypothalamus, the hippocampus and the 
cerebral cortex (Morris 1989). NPY contributes to a wide array of physiological and 
pathological conditions (Morales-Medina et al. 2010, Morales-Medina et al. 2011) 
including somatosensory processing (Hokfelt et al. 2007, Taylor 2009).  A broad spectrum 
of physiological effects of NPY in mammals is mediated by at least five GPCRs (Y1R, Y2R, 
Y4R Y5R, and Y6R (Michel et al. 1998). Of the NPY receptor subtypes, Y1R has received 
the most attention in pain research (Hokfelt et al. 2007, Smith et al. 2007), because of its 
high expression in both CNS and PNS pain circuitry. Y1R is coupled to Gαi/o, leading to 
inactivation of adenylyl cyclase and the subsequent reduction of cAMP. In addition, it can 
inhibit N- and P/Q-type Ca2+ channels (Wang 2005). Moreover, Y1R activates G-protein-
coupled, inwardly rectifying potassium channels (GIRKs) (Sun et al. 2001), and mitogen-
activated protein kinase (MAPK) (Nie et al. 1998) pathways. It is generally accepted that 
Y1R activation overall decreases the excitability of a neuron (Brumovsky et al. 2007).  
 
1.3.1.1  NPY and Y1R expression in the dorsal horn and DRGs 
NPY expression in the dorsal horn is described in detail in Section 1.2.4.3. NPY is 
normally undetectable or present in very low levels in the DRG (Wakisaka et al. 1991). 
Y1R is the only NPY receptor that is highly expressed in spinal neurons (Naveilhan et al. 
1998, Hokfelt et al. 2007). At least seven different types of cells express Y1R in the dorsal 
horn, with the most intense Y1R expression at Lamina II (Brumovsky et al. 2006). 
Approximately 70% of Y1 neurons in lamina II co-express somatostatin (Zhang et al. 
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1999), and therefore are presumably glutamatergic (Todd et al. 2003, Hokfelt et al. 2007). 
In DRGs, 
 Y1R is expressed in the cell bodies of peptidergic DRG neurons (Brumovsky et al. 
2005, Brumovsky et al. 2007), although its transport to the central terminals is uncertain 
(Taylor et al. 2014). 
 
1.3.1.2  Change of NPY and Y1R expression after inflammation 
The effect of intraplantar injection of CFA on NPY expression in the dorsal horn 
remains unclear due to conflicting reports (Wakisaka et al. 1992, Ji et al. 1994). Initial 
studies reported that intraplanter CFA has no effect on NPY-Li in rat DRG (Wakisaka et 
al. 1992). However, in the mono-iodoacetate experimental model of osteoarthritis, NPY 
expression is increased in L3-L5 rat DRG 3-7 days post-injection (Ferreira-Gomes et al. 
2012). Intraplanter CFA upregulates Y1R mRNA in the rat dorsal horn and DRG (Ji et al. 
1994). Thus, although controversy exists for NPY, there is consensus that Y1Rs are 
upregulated upon peripheral inflammation. 
 
1.3.1.3  Change of NPY and Y1R expression after nerve injury 
Various models of neuropathic pain increase NPY levels in the dorsal horn, including 
constriction injury (CCI)  (Wakisaka et al. 1992, Ma et al. 1998), partial sciatic nerve 
ligation (PSNL) (Ma et al. 1998, Ma et al. 2000),  spared nerve injury (SNI) (Intondi et al. 
2010), spinal nerve ligation (SNL) (Ossipov et al. 2002, Wang et al. 2012), and sciatic 
nerve crush injury (Wakisaka et al. 1992). In all studies mentioned above, nerve damage 
increases NPY immunoreactivity in DRG, suggesting a possible source for NPY increase 
in the dorsal horn. Spontaneous ectopic impulses are commonly observed in regenerating 
or damaged fibers after nerve injury (Kajander et al. 1992, Kajander et al. 1992). Ectopic 
activity of large diameter primary afferents leads to the spontaneous release of NPY into 
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the dorsal horn after nerve injury (Mark et al. 1998). This mechanism may account, at least 
partially, for the increase of NPY in dorsal horn.  
Peripheral nerve injury does not change Y1R expression in the dorsal horn 
(Brumovsky et al. 2004). Nerve injury does decrease Y1R transcript levels in the DRG of 
rat and monkey (Zhang et al. 1994, Landry et al. 2000, Brumovsky et al. 2004), but this is 
not replicated in mouse (Shi et al. 1998, Shi et al. 2006). Chapter 4 hypothesizes that 
nerve injury strengthens the NPY-Y1R axis by increasing NPY release. 
 
1.3.2  Endogenous NPY-Y1 axis and pain inhibition 
NPY receptor analgesia is an endogenous mechanism that might prevent the 
transition from acute to chronic pain (Solway et al. 2011). In the short term setting of acute 
pain, it is well established that tissue injury produces not only CS, but also opposing 
mechanisms involving the spinal release of inhibitory peptides (Basbaum et al. 1984, 
Ossipov et al. 2010) and µ-opioid receptor activation (Heinke et al. 2011), thus providing 
an endogenous braking mechanism that exerts inhibitory control of acute pain intensity 
(Ossipov et al. 2010). However, only until recently was it established that NPY signaling 
could be maintained long enough to oppose chronic pain (Solway et al. 2011). We used a 
small amount of CFA (5 ul) or a mild variant of the SNI model (CpxSx) so hyperalgesia 
(decrease in mechanical response threshold to von Frey filament stimulation) would 
resolve quickly. A previous publication from our lab indicated that either intrathecal 
delivery of NPY receptor antagonists or conditional genetic NPY depletion reinstates 
hyperalgesia (Solway et al. 2011). This effect was associated with an enhancement of 
Y1R GPCR signaling (Taylor et al. 2014). These data suggest that injury increases NPY 
receptor--G-protein pain inhibitory signaling in dorsal horn that maintains LS in a lasting 
state of remission. Thus, any event that interferes with spinal NPY-Y1R analgesia could 
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unleash a pain episode indicative of chronic pain relapse (Figure 1-3). Understanding how 
an organism can naturally recover from acute pain is of great importance for novel 
therapeutic target development. Therefore, in Chapter 2 and 3, we will study the 
mechanism of how the LS is controlled by endogenous NPY system at the spinal level.  
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CHAPTER 2:  Protein Kinase A and EPAC mediate latent sensitization after injury: 
prolonged inhibition by endogenous Y1 receptors in dorsal horn 
 
2.1  Introduction 
Peripheral injury-induced spinal central sensitization (CS) (Ji et al. 2003, Latremoliere 
et al. 2009) may last beyond the restoration of pain threshold. Even though pain may have 
apparently resolved, subsequent injury or stressors can reveal vulnerability to enhanced 
allodynia or hyperalgesia, referred to as latent sensitization (LS) (Mishima et al. 1997, Aley 
et al. 2000, Rivat et al. 2002, Parada et al. 2003, Rivat et al. 2007, Summer et al. 2007, 
Cabanero et al. 2009, Reichling et al. 2009, Le Roy et al. 2011, Corder et al. 2013). LS 
could contribute to the mechanisms responsible for the transition from acute to chronic 
pain, and is found in humans (Pereira et al. 2015). This highlights the clinical importance 
to better understand its underlying mechanisms; however, the cellular and molecular 
mechanisms of LS remain largely unknown.  
LS can be unmasked with disinhibition of nociceptive systems, and a prime example 
of this is observed after disruption of the neuropeptide tyrosine (NPY) system (Solway et 
al. 2011). Both genetic (NPY depletion) or pharmacological [intrathecal administration of 
an NPY Y1 receptor (Y1R) antagonist] disruption of the spinal NPY-Y1R signaling cascade 
(which we refer to as the NPY-Y1R axis) reinstates pain during the remission phase of LS. 
Solway et al. concluded that the NPY-Y1R axis serves as an endogenous inhibitory brake 
on LS, thus keeping pain in remission. This dissertation seeks to unravel the underlying 
mechanisms, for which we have very little understanding. 
 The Y1R is a member of the G protein coupled receptor (GPCR) superfamily and 
couples to inhibitory G-proteins αi/o, leading to the inactivation of adenylyl cyclase and 
subsequent down regulation of cAMP (Grouzmann et al. 2001, Silva et al. 2002). Adenylyl 
cyclase type 1 (AC1) is found in superficial laminae of spinal cord and activated by 
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Ca2+/calmodulin following N-Methyl-D-aspartate receptors (NMDAR) activation, 
contributing to inflammatory and neuropathic pain (Wei et al. 2002, Wang et al. 2011). 
Previous findings from our lab suggest that NMDAR-dependent AC1 superactivation 
contributes to the LS driven by prolonged endogenous µ-opioid receptor signaling after 
inflammation (Corder et al. 2013). We propose a similar inhibitory mechanism involving 
prolonged Y1 signaling after inflammation or nerve injury. My first hypothesis is that 
endogenous NPY-Y1 axis maintains LS in the remission state by inhibiting NMDAR-
dependent AC1 superactivation. 
cAMP has been well established to activate protein kinase A (PKA), which is heavily 
involved in CS (Aley et al. 1999, Latremoliere et al. 2009). In addition, recent studies 
suggest a new exciting receptor target: the exchange protein directly activated by cAMP 
(Epac) (Dodge-Kafka et al. 2005, Chen et al. 2013). An emerging literature suggests that 
Epac critically contributes to pain (Griffin 2005, Hucho et al. 2005, Eijkelkamp et al. 2010, 
Eijkelkamp et al. 2013, Wang et al. 2013, Gu et al. 2016, Singhmar et al. 2016). These 
publications led to my second hypothesis that both PKA and Epac are essential to LS, 
which is silenced by the pain inhibitory NPY-Y1 axis. 
The TRPA1 and TRPV1 channels can be sensitized upon injury (Palazzo et al. 2012, 
Park et al. 2014, Spahn et al. 2014). They often co-localize on small C and Aδ nociceptors 
including their central terminals (Szallasi et al. 1995, Caterina et al. 1997, Guo et al. 1999, 
Szallasi et al. 1999, Valtschanoff et al. 2001), facilitating nociceptive transmission 
(Caterina et al. 2000, Davis et al. 2000, Chuang et al. 2001, Moriyama et al. 2003, Bolcskei 
et al. 2005, Amadesi et al. 2006, Palazzo et al. 2012). The 35% Y1R expressing DRG 
cells also express TRPV1 (Gibbs et al. 2004).  In vitro studies suggest that Y1R activation 
down-regulates TPRV1/A1-induced Ca2+ mobilization (Xu et al. 2008, Xu et al. 2010) or 
calcitonin-gene related peptide (CGRP) release (Gibbs et al. 2004, Gibbs et al. 2006, 
Gibbs et al. 2008). In addition, PKA phosphorylation of either channel can sensitize them 
24 
 
 
to injury (Yao et al. 2005, Rosenbaum et al. 2007, Lapointe et al. 2011). Thus, my third 
hypothesis is that TRPA1 and V1 channels contribute to LS, which is silenced by the NPY-
Y1 axis. 
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2.2  Materials and Methods 
2.2.1  Animals 
     All animals were housed 2-4 per cage, with same-sex littermates, in a lighting (14-h 
light/dark cycle), temperature (68-72º F) and humidity controlled room with food and water 
provided ad libitum (with the exception of NPYtet/tet mice). Animals were allowed a minimum 
of one week to habituate to the facility prior to their entrance into the study. Only mice 
were used in this study. All animal procedures were approved by the Institutional Animal 
Care and Use Committee of the University of Kentucky, followed the guidelines for the 
treatment of animals of the International Association for the Study of Pain, and conducted 
in full compliance with the Association for Assessment and Accreditation of Laboratory 
Animal Care. 
 
2.2.1.1  Wildtype (WT) mice 
This study used naïve WT male C57BL/6 mice purchased from Charles Rivers 
(Indianapolis), 18-20 g when studies began. Animals were allowed a minimum of one 
week to habituate to the facility prior to their entrance into the study.  
 
2.2.1.2  AC1 knockout (KO) mice 
As previously described (Corder et al. 2013), breeding pairs of AC1-/- mice were kindly 
provided by Dr. Daniel Storm (Washington University, Seattle, WA, USA), and bred at our 
facility using a congenic strategy onto a C57BL/6 background. Male homozygous and their 
WT littermates were used in this study at the age of 8-12 weeks when the studies started. 
Genotype was confirmed twice, before and after each study by a tail-snip PCR. 
 
 
26 
 
 
2.2.1.3  NPY tet/tet mice 
As previously described (Solway et al. 2011), heterozygous breeding pairs of NPY null 
(Erickson et al. 1996), and Npytet/tet mice (Ste Marie et al. 2005) were kindly provided by 
Dr. Richard Palmiter (University of Washington, Seattle, WA). Speed congenics were used 
to generate Npytet/tet on a C57BL/6 background in our facility. The mouse line was 
maintained in our facility by crossing homozygous male Npytet/tet with hemizygous females 
(we found that homozygous females do not breed well, Renee Donahue, personal 
communication). Number of progeny per litter was small (2-4 pups), but reliable. Male 
homozygous and their WT littermates were used in this study. Genotype was confirmed 
twice before and after each study by a tail-snip PCR. 
 
2.2.2  Doxycycline Administration to NPYtet/tet Mice 
 Npytet/tet mice were provided drinking water with saccharin (5 mM; Sigma-Aldrich, St 
Louis, MO) or saccharin + Doxycycline hyclate (Dox, 2 mg/mL, prepared fresh every three 
days, Sigma-Aldrich, St Louis, MO) 7 days prior to SNI surgery. Saccharin was added to 
enhance palatability of Dox. Weight of the animals was monitored daily within 3 days after 
Dox/saccharin water feeding. Dehydrated animals (defined by 20 % body weight loss) due 
to the flavor change of water were removed from the study. Delivery of Dox or saccharin 
in the drinking water does not change the development or intensity of behavioral signs of 
mechanical or cold allodynia following SNI administration as described previously (Solway 
et al. 2011). 
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2.2.3  Animal Models of Persistent Pain 
2.2.3.1  Complete Freund’s Adjuvant (CFA) Model of Inflammatory Pain 
 Mice were injected subcutaneously with 5 µl CFA (1mg/ml, Sigma-Aldrich, St. Louis, 
MO) into the midplantar region of the left hindpaw with a 30G needle. Sham CFA involved 
restriction of the animals with left hindpaw pulled back for 1 min.  
 
2.2.3.2  Spared Nerve Injury Models (SNI and CpxSx) of Neuropathic Pain 
SNI surgeries were performed as previously described (Decosterd et al. 2000). Briefly, 
anesthesia was induced with 5% isoflurane and maintained with 3% isoflurane throughout 
surgery.  After shaving of the left hind limb and both Betadine and Alcohol wipe, an incision 
was made in the skin at the level of the trifurcation of the sciatic nerve of the left hindpaw. 
The overlying biceps femoris muscles were retracted to expose the common peroneal, 
tibial, and sural nerves. With care taken to avoid perturbation of the sural branch, the 
common peroneal and tibial nerves were ligated with 6.0 silk suture (Ethicon, Somerville, 
NJ), followed by transection of 1 mm of each nerve at either end of each knot. The knot 
with the transected nerve piece was removed. The muscle was sutured with absorbable 
6-0 sutures (Ethicon) and the wound was closed with 9mm metal clips. Rats were 
monitored for the following 3 days. The metal clips were removed 10 days after the 
surgery. Behavioral testing was conducted at 7 (neuron/glia study) or 14 days (other 
studies) post-SNI, and rats that failed to develop mechanical hyperalgesia (~20%) were 
removed from the study. Alternatively, the common peroneal and sural nerves of the left 
hindpaw were ligated and transected, sparing the tibial nerve (CpxSx) (Shields et al. 2003). 
 
2.2.4  Pain-Like Behavior Testing 
 All animals were acclimated to a stainless steel grid within individual Plexiglas tubes 
for at least 60 min prior to behavioral testing. 
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2.2.4.1  Mechanical Threshold.  
To evaluate sensitivity to a non-noxious mechanical stimulus, we used an incremental 
series of 8 von Frey filaments (Stoelting, Inc, Wood Dale, IL) of logarithmic stiffness 
(0.008-6 grams).  The 50% withdrawal threshold was determined using the up-down 
method (Chaplan et al. 1994).  Each filament was applied perpendicular to the central (for 
CFA and CpxSx model) or lateral (innervated by the sural branch of the sciatic nerve, for 
SNI model) plantar skin of the hindpaw surface with sufficient force to cause a slight 
bending of the filament. A positive response was defined as a rapid withdrawal of the paw 
within a count of 5 seconds, as silently counted by the experimenter. 
 
2.2.4.2  Response to Cool Stimulation.  
Using a syringe connected to PE-90 tubing, flared at the tip to a diameter of 2 mm, a 
drop of acetone was carefully applied to the plantar paw. Surface tension maintained the 
drop volume to 5 to 8 μL as measured by Weisi Fu. The duration of paw withdrawal was 
recorded with a 45 sec cutoff. Three observations, collected 5 min apart, were averaged.  
 
2.2.5  Intrathecal (i.t.) Drug Administration 
 Intrathecal injection was performed in lightly restrained unanesthetized mice as 
previously described (Fairbanks 2003). Briefly, a 30 G needle attached to a Hamilton 
microsyringe was inserted between L5/L6 vertebrae, puncturing the dura (confirmed by 
presence of reflexive tail flick). We then injected a 5 µl volume of vehicle or drug. The data 
of Figure 2-2 and 2-6 include animals that were injected twice using a cross-over design 
with a 7-day separation between two injections. Animals receiving vehicle for the first 
injections received drug for the second, and animals receiving drug for the first injections 
received vehicle for the second. In all cases, group means of vehicle and drug did not 
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differ on either injection day, and so were combined for final analysis. The data of Figure 
2-1 were obtained on Day 21 (CFA) or 28 (CpxSx) after two i.t. injections, each separated 
by 15 min.  
 
2.2.6  Drug Dosing 
The following drugs and doses were used for intrathecal injections: BIBO 3304 
trifluoroacetate (BIBO, Tocris Biosciences, United Kingdom), 5 µg/5 µl; (+)-MK-801 
hydrogen maleate (MK-801, Sigma-Aldrich, St Louis, MO), 1 µg/5 µl (this dose of MK801 
was devoid of overt motor effects); NB001 (Sigma-Aldrich, St Louis, MO), 1.5 µg/5 µl; N⁶ - 
Benzoyladenosine- 3', 5'- cyclic monophosphate (6-Bnz-cAMP), sodium salt Membrane-
permeant (6Bnz, BIOLOG Life Science Institute, Bremen, Germany), 10 nmol/5 µl; H-89 
dihydrochloride hydrate (H89, Sigma-Aldrich, St Louis, MO), 10, 30 nmol/5 µl; 8-(4-
Chlorophenylthio)-2'-O-methyladenosine 3',5'-cyclic Monophosphate sodium salt (8cpt, 
Enzo Life Sciences, United Kingdom), 3 nmol/ 5 µl; ESI-09 and HJC0197 (Courtesy of Jia 
Zhou, University of Texas Medical Branch), 10 µg/5 µl; HJC0350 (Courtesy of Jia Zhou, 
University of Texas Medical Branch), 1 µg/5 µl; HC 030031 (Tocris Biosciences, United 
Kingdom) 10 µg/5 µl; AMG 9810 (Tocris Biosciences, United Kingdom) 1, 10 nmol/5 µl. 
Vehicle used for Figure 2-4A and 2-5A was saline; vehicle used for Figure 2-5B-D, 2-6, 2-
7, and 2-9A was ethanol: alkamuls EL-620 (Rhodia, Cranbury, NJ): saline in a volume 
ratio of 2:2:6; vehicle used for other experiments was ethanol: alkamuls EL-620: saline in 
a volume ratio of 1:1:8. 
 
2.2.7  Blinding procedure  
The experimenter, Weisi Fu, was blinded to drug treatments in all behavioral 
pharmacology experiments by another personal in lab. Briefly, all drugs and vehicle was 
made in identical tubes. A lab mate color-coded the tubes for Weisi. The key for coding 
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was kept hidden in the notebook/blinder until the completion of the experiment. Weisi then 
obtained the key for data analysis. 
 
2.2.8  Statistics 
 Differences between means were analyzed by two-way analysis of variance (ANOVA) 
(Figure 2-1—2-8, and 2-10), as indicated in the figure legends. Drug/Dose/Gene was a 
grouping factor and time was the repeated measure. If a significant interaction or group 
was found (p < 0.05), the ANOVA was followed by Bonferroni’s (for 2-group comparison) 
or Turkey’s post-hoc (for multi-group comparison) tests. Figure 2-9 was analyzed by 
Student’s t test (Graphpad Prism v7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
2.3  Results 
2.3.1  Endogenous NPY-Y1R axis maintains LS in remission by inhibiting NMDAR-
dependent AC1 superactivation 
2.3.1.1  NMDAR activity is required for the induction of pain reinstatement produced by 
inhibition of Y1R signaling   
NMDAR-Ca2+-AC1-cAMP signaling was found to be required to maintain LS after 
peripheral inflammation, inhibited by endogenous constitutive µ-opioid receptor signaling 
(Corder et al. 2013). To test the hypothesis that prolonged endogenous NPY-Y1 signaling 
suppresses NMDAR-dependent AC1 superactivation to keep LS in remission after 
inflammatory or nerve injury, we first asked whether NMDAR activity is required for the 
induction of pain reinstatement produced by inhibition of Y1R signaling. 
As illustrated in Figure 2-1, mechanical hyperalgesia was confirmed three days after 
CFA injection on the hindpaw. Threshold then returned to pre-injection baseline level by 
day 21. During this remission phase (e.g. after resolution of inflammatory mechanical 
hyperalgesia), I performed a behavioral pharmacology experiment with two consecutive 
intrathecal deliveries of vehicle or drugs (the activity-dependent NMDAR blocker, MK801, 
or the Y1R antagonist, BIBO3304), separated by 15 min (Figure 2-1A). BIBO3304 does 
not change mechanical threshold in CFA sham mice (Kuphal et al. 2008). Consistent with 
our previous findings (Solway et al. 2011), BIBO3304 reinstated mechanical hyperalgesia 
at both 30 (p = 0.0004) and 60 (p = 0.0003) min after i.t. injection (Drug X Time; F3, 25 = 
8.643; p = 0.0004). Most importantly, MK801 abolished the reinstatement induced by 
BIBO3304 at both time points (p < 0.0001, p = 0.002, respectively). 
Similarly, as illustrated in Figure 2-1B and C, and using a relatively mild version of 
spared nerve injury (the CpxSx model), mechanical hyperalgesia and cold allodynia were 
confirmed 2 weeks after surgery; thresholds returned to pre-injury baseline at day 28. As 
described above, during this remission phase of neuropathic pain, I performed a 
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behavioral pharmacology experiment with two consecutive intrathecal injections of vehicle 
or drugs (MK801 or BIBO3304), separated by 15 min. BIBO3304 changed neither 
mechanical (Figure 2-1B) nor cold (Figure 2-1C) thresholds in CpxSx sham mice. 
Consistent with our previous findings (Solway et al. 2011), BIBO3304 reinstated 
mechanical (Figure 2-1B) and cold (Figure 2-1C) hypersensitivity at both 30 (p = 0.015) 
and 60 (p = 0.027) min after i.t. injection (Drug X Time; F4, 27 = 2.792; p = 0.046) in CpxSx, 
but not sham mice (p > 0.05). Most importantly, MK801 abolished the reinstatement of 
hypersensitivity induced by BIBO3304 injection at both time points (p = 0.0058, p = 0.049, 
respectively). At this dose (1 µg), MK801 alone did not change mechanical or cold 
thresholds nor did it produce motor function side effects in either the CFA or CpxSx models. 
These results lead us to conclude that in both inflammatory and neuropathic pain 
models, the endogenous NPY-Y1 axis exerts an anti-nociceptive mechanism that 
counteracts NMDAR-mediated pro-nociceptive signaling to keep LS in remission. 
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Figure 2-1. NMDAR activity is required for the induction of pain reinstatement 
produced by inhibition of Y1R signaling   
At 21 days after induction of CFA (A) or 28 days after CPxSx (B, C), MK801 (MK, 1 µg/5 
µl, i.t.) or vehicle (Veh) was administered. 15 min later, BIBO3304 (BIBO, 5 µg/5 µl i.t.) or 
vehicle was injected. MK-801 prevented BIBO3304-induced reinstatement of mechanical 
hypersensitivity in CFA (A) and CPxSx (B) mice, and cold hypersensitivity in CPxSx (C) 
mice. A) Time course of mechanical thresholds at pre-injection baseline, d3, d21 after 
CFA induction, and 30 and 60 min after the 2nd i.t. injection. B, C) Time course of 
mechanical (B) and cold (C) thresholds at pre-surgery baseline, d14, d28 after CpxSx 
surgery, and 30 and 60 min after the 2nd i.t. injection. Values represent mean ± SEM. n=4-
10. P < 0.05 (CpxSx vs sham group), P < 0.05 (Injury MK + BIBO vs Injury Veh + BIBO 
group), #P < 0.05 (Veh + BIBO vs Veh + Veh group), Bonferroni’s post-hoc tests following 
repeated measures of 2-group 2-way ANOVA. Turkey’s post-hoc tests following repeated 
measures of multi-group 2-way ANOVA.  
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2.3.1.2  AC1 is required for the induction of pain reinstatement produced by inhibition of 
Y1R signaling   
Next, we asked the question as to whether AC1 is required for the pain reinstatement 
that follows Y1R antagonism. To test this, I initially utilized AC1 knockout mice. As 
previously described (Wei et al. 2002, Corder et al. 2013) and shown in Figure 2-2, I 
observed no differences in mechanical thresholds or cold responses between AC1KO and 
WT mice. This suggests that AC1 is not required for the expression of acute nociception 
(P > 0.05). After inflammation, AC1KO mice developed a similar intensity of mechanical 
hyperalgesia as compared with WT mice (Figure 2-2A) at early timepoints (d1-3, P > 0.05), 
but recovered within one week, much sooner than WT mice (Gene X Time, F1, 14 = 4.932; 
p = 0.0434). After CpxSx, AC1 gene deletion did not reduce mechanical (Figure 2-2B, Gene 
X Time, F1, 20 = 1.391; p = 0.2520) or cold (Figure 2-2C, Gene X Time, F1, 20 = 2.148; p = 
0.1583) hypersensitivity. Strikingly, AC1 deletion prevented the ability of BIBO3304 to 
reinstate mechanical hyperalgesia when administered during the pain remission phase in 
either the CFA (Fig, 2-2A, Gene X Time, F1, 26 = 20.5; p = 0.0001) or the CpxSx (Figure 2-
2B Gene X Time, F1, 23 = 11.72, p = 0.0023) model. In addition, AC1 deletion abolished the 
ability of BIBO3304 to reinstate cold allodynia in CpxSx model (Figure 2-2C Gene X Time, 
F1, 26 = 8.31; p = 0.0018). 
To determine whether the site of action of AC1 is at the spinal cord, I then intrathecally 
injected NB001, a selective AC1 inhibitor (Wang et al. 2011), together with BIBO3304 
(Figure 2-3). Similar to the AC1 deletion effect, NB001 abolished the ability of BIBO3304 
to reinstate mechanical hyperalgesia when administered during the pain remission phase 
in the CFA model (Figure 2-3A, Gene X Time, F1, 9 = 10.24; p = 0.0108). In addition, AC1 
deletion abolished the ability of BIBO3304 to reinstate mechanical hyperalgesia (Figure 
2-3B, Gene X Time, F1, 12 = 22.81, p = 0.0005) and cold allodynia (F1, 26 = 18.75; p = 0.001) 
in the CpxSx model.  
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These results suggest that AC1 is required for the induction of pain reinstatement that 
follows Y1R antagonism. Altogether, we conclude that prolonged endogenous NPY-Y1 
signaling suppresses NMDAR-dependent AC1 superactivation to keep LS in remission 
after inflammatory or nerve injury. 
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Figure 2-2. AC1 knockout abolishes Y1R-antagonist-induced reinstatement of 
inflammatory and neuropathic pain 
A) Progression of CFA induced mechanical hyperalgesia and effect of i.t. BIBO3304 
(BIBO, 5 µg/5 µl i.t) when administered during pain remission in AC1KO mice and their 
WT littermates. B, C) Progression of CpxSx-induced mechanical (B) and cold (C) 
hypersensitivity and effect of i.t. BIBO when administered during pain remission in AC1KO 
mice and their WT littermates. All animals were injected twice using a cross-over design 
with 7-day separation between the two i.t. injections. Values represent mean ± SEM. n=12-
16. P < 0.05 (AC1KO vs WT group), P < 0.05 (AC1KO-BIBO vs WT-BIBO group), 
Bonferroni’s post-hoc tests following repeated measures of 2-way ANOVA. 
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Figure 2-3. Inhibition of AC1 prevents Y1R-antagonist-induced reinstatement 
At 21 days after induction of CFA (A) or 28 days after CPxSx (B, C), drugs were 
administered together in a single i.t. injection. NB001 (1.5 µg) prevented BIBO3304-
induced reinstatement of mechanical hypersensitivity in CFA (A) and CPxSx (B) mice, and 
cold hypersensitivity in CPxSx (C) mice. A) Time course of mechanical thresholds at pre-
injection baseline, d3, d21 after CFA induction, and 30 and 60 min after the i.t. injection. 
B, C) Time course of mechanical (B) and cold (C) thresholds at pre-surgery baseline, d14, 
d28 after CpxSx surgery, and 30 and 60 min after the i.t. injection. Values represent mean 
± SEM. n=5-7. P < 0.05 (NB001+BIBO vs BIBO group), Bonferroni’s post-hoc tests 
following repeated measures of 2-way ANOVA.  
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2.3.2  PKA contributes to LS that is inhibited by the endogenous NPY-Y1 axis. 
Consistent with previous findings (Corder et al. 2013), the above results demonstrate 
that NMDAR-Ca2+-AC1-cAMP signaling pathway drives LS. As a well-known cAMP 
effector, PKA was selected to be our next candidate in the signaling pathway that drives 
LS. To test this hypothesis, as illustrated in Figure 2-4, I intrathecally administered the 
selective PKA activator, 6-Bnz-cAMP (6Bnz) to CFA and sham day 21 mice (Figure 2-4A). 
I chose a dose (10 nmol) that does not produce mechanical hyperalgesia in sham mice. 
This dose of 6Bnz reinstated mechanical hyperalgesia in CFA day 21 mice (Group X Time; 
F2, 20 = 5.571; p = 0.0119). To confirm that the reinstatement produced by 6Bnz is through 
the activation of PKA, I injected the PKA inhibitor H89 to block the 6Bnz effect (Figure 2-
4B). I found that H89 dose-dependently inhibited the reinstatement produced by 6Bnz in 
CFA day 21 mice (Group X Time; F3, 29 = 6.364; p = 0.0019). Thus, during LS, PKA is in a 
silenced superactive state, and an activator of it is sufficient to override inhibitory systems 
to reveal LS. 
We then tested the hypothesis that the PKA-driven LS is under the inhibitory control 
of the endogenous NPY-Y1 axis. To test this, as illustrated in Figure 2-4C, I intrathecally 
administered H89 together with the Y1 antagonist BIBO3304 in CFA day 21 mice. I found 
that co-administration of H89 attenuated BIBO3304-induced reinstatement of mechanical 
hyperalgesia (Group X Time; F3, 38 = 5.965; p = 0.002). Thus, we conclude that a 
superactive PKA system is under the inhibitory control of NPY-Y1R axis during LS.  
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Figure 2-4. PKA is essential to drive LS, silenced by endogenous Y1R signaling 
At 21 days after induction of CFA or sham, drugs were administered in one single i.t. 
injection. A) 10 nmol 6Bnz reinstated mechanical hyperalgesia in CFA but not sham day21 
mice n=6-8. P < 0.05 (CFA 6Bnz vs sham 6Bnz group). B) H89 (30 nmol) blocked the 
6Bnz (10 nmol) effect in CFA day 21 mice. n=4-12. P < 0.05 (30 nmol H89 + 6Bnz vs 
6Bnz group). C)  H89 (10 nmol) attenuated the BIBO3304 (BIBO, 5 µg) reinstatement of 
mechanical hyperalgesia in CFA day 21 mice. n=8-12. P < 0.05 (H89 + BIBO vs BIBO 
group). Values represent mean ± SEM. Bonferroni’s post-hoc tests following repeated 
measures of 2-way ANOVA.  
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2.3.3  NPY-Y1R axis maintains LS in remission by inhibiting TRPA1 
The above results demonstrate that the NMDAR-AC1-PKA signaling pathway drives 
LS, and this is under the inhibitory control of the endogenous NPY-Y1R axis. TRPA1 is 
implicated in many pain conditions (Kwan et al. 2006, Basbaum et al. 2009). PKA 
phosphorylation is required for TRPA1 activation or sensitization under several pain-
related circumstances (Wang et al. 2008, Schmidt et al. 2009, Chen et al. 2011). These 
evidences lead to my next hypothesis that TRPA1 contributes to the LS that is masked by 
the endogenous NPY-Y1R axis.  
To test this hypothesis, I first intrathecally injected HC030031, a TRPA1 antagonist, 
together with BIBO3304 (Figure 2-5) during pain remission in both CFA and CpxSx 
models. I found that HC030031 attenuated the BIBO3304 reinstated mechanical 
hyperalgesia in the CFA model (Figure 2-5A, Group X Time, F3, 30 = 7.398; p = 0.0008). In 
addition, HC030031 attenuated the BIBO3304-induced reinstatement of mechanical 
hyperalgesia (Figure 2-5B, Group X Time, F4, 33 = 13.8; p < 0.0001) and cold allodynia (Fig. 
2-5C, Group X Time, F4, 34 = 10.21; p < 0.0001) in the CpxSx model. Thus, we conclude 
that TRPA1 contributes to the LS that is masked by the endogenous NPY-Y1R axis.  
To complement the pharmacological studies of Figure 2-5 and confirm the contribution 
of TRPA1 to LS, I used conditional NPY knockdown mice with replacement of the native 
NPY promotor with an artificial tonically-active promotor containing a 
tetracycline/doxycycline regulatory site (NPYtet/tet). As illustrated in Figure 2-6, consistent 
with our previous observation (Solway et al. 2011), continuous exposure to Doxycycline 
(Dox) in the drinking water essentially silenced artificial NPY promotor-driven expression 
in dorsal horn (Figure 2-6A and B). At 8-11 weeks after spared nerve injury (SNI), Dox in 
the drinking water (started 7 days before SNI) increased both mechanical (Figure 2-6C, 
Gene X Time, F1, 11 = 18.68; p = 0.0012) and cold (Figure 2-6D, Gene X Time, F1, 11 = 
44.15; p < 0.0001) hypersensitivity in NPY tet/tet mice. This confirms the results of our 
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previous publication showing that NPY tonically masks latent sensitization. Next, to 
evaluate the contribution of TRPA1 to the LS that is masked by NPY, I intrathecally 
delivered the TRPA1 antagonist, HC030031 in control and NPY knockout mice. I found 
that HC030031 but not vehicle attenuated mechanical (Figure 2-6C, Drug X Time, F1, 12 = 
4.872; p = 0.0475) and reversed cold (Figure 2-6D, Drug X Time, F1, 12 = 9.872; p = 0.0085) 
hypersensitivity in NPY knockdown but not control mice. HC0300031 completely reversed 
the effect of NPY knockdown on the cold modality of LS of (Figure 2-6D), but only partially 
reduced the mechanical modality of LS (Figure 2-6C); we suggest that TRPA1 exerts a 
greater influence on the cold, as compared to the mechanical component of the LS that is 
masked by the NPY-Y1R axis. In summary, this data supports our hypothesis that 
endogenous NPY receptor signaling inhibits TRPA1-mediated LS. Furthermore, we 
speculate that in control mice, endogenous NPY signaling has exhausted its capacity to 
inhibit TRPA1 in the neuropathic pain state, because HC0300031 failed to further reduce 
hypersensitivity in control mice 8-11 weeks after SNI. 
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Figure 2-5. TRPA1 antagonism attenuates Y1R-antagonist-induced 
reinstatement of inflammatory and neuropathic pain 
At 21 days after induction of CFA (A) or 28 days after CPxSx (B, C), drugs were 
administered in one single i.t. injection. HC030031 (HC, 10 µg) attenuated BIBO3304-
induced reinstatement of mechanical hypersensitivity in CFA (A) and CPxSx (B) mice, and 
cold hypersensitivity in CPxSx (C) mice. A) Time course of mechanical thresholds at pre-
injection baseline, d3, d21 after CFA induction, and 30 and 60 min after the i.t. injection. 
B, C) Time course of mechanical (B) and cold (C) thresholds at pre-surgery baseline, d14, 
d28 after CpxSx surgery, and 30 and 60 min after the i.t. injection. Values represent mean 
± SEM. n=6-10. P < 0.05 (CpxSx vs sham group), P < 0.05 (Injury HC+BIBO vs Injury 
BIBO group). Bonferroni’s post-hoc tests following repeated measures of 2-group 2-way 
ANOVA. Turkey’s post-hoc tests following repeated measures of multi-group 2-way 
ANOVA.  
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Figure 2-6. TRPA1 antagonism reduces NPY knockdown-induced reinstatement 
of neuropathic pain. 
Transverse sections of lumbar spinal cord (L4–L6) taken from ipsilateral side of 
NPYtet/tet mice 14 days after SNI [continuous exposure of saccharine- (Sac, A) or 
Doxycycline- (Dox, B) containing water started 7 days before SNI] were labeled with 
antibody against NPY. A, B) examples of NPY staining in the dorsal horn. Scale bar: 50 
µm. 8-11 Week after SNI, HC030031 (10 µg) or vehicle was intrathecally administered. 
HC030031 attenuated mechanical (C) and cold (D) hypersensitivity in NPY knockdown 
mice, but not in control mice. C, D) Progression of SNI induced mechanical (C) and cold 
(D) hypersensitivity and effect of i.t. HC030031 in NPY knockdown and control mice. All 
animals were injected twice using a cross-over design with 7-day separation between two 
i.t. injections. P < 0.05 (NPYtet Dox vs NPYtet Sac), P < 0.05 (NPYtet Dox HC vs 
NPYtet Dox veh group). Bonferroni’s post-hoc tests following repeated measures of 2-way 
ANOVA. n=6-7. 
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2.3.4  NPY-Y1R axis maintains LS in remission by inhibiting TRPV1 
Similar to TRPA1, phosphorylation of TRPV1 by PKA causes sensitization or reduction 
of desensitization of the channel. As a result, the responsiveness of pain-processing 
neurons is increased, and adaptation during pain perception is affected. (Lopshire et al. 
1998, Bhave et al. 2002, Rathee et al. 2002, Mohapatra et al. 2003, Mohapatra et al. 2005, 
Yao et al. 2005). These evidences lead to our next hypothesis that TRPV1 contributes to 
the LS that is masked by the endogenous NPY-Y1R axis. To test this hypothesis, I 
intrathecally injected AMG9810, a TRPV1 antagonist, together with BIBO3304 (Figure 2-
7) during pain remission in both CFA and CpxSx models. I found that AMG9810 dose-
dependently attenuated the BIBO3304-induced reinstatement of mechanical hyperalgesia 
in the CFA model (Figure 2-7A, Group X Time, F4, 29 = 19.38; p < 0.0001). In addition, 
AMG9810 attenuated the BIBO3304-induced reinstatement of mechanical hyperalgesia 
(Figure 2-7B, Group X Time, F4, 34 = 9.964; p < 0.0001) but not cold allodynia (Figure 2-
7C) in the CpxSx model. These data indicate that TRPV1 contributes to mechanical LS, 
but may not contribute to cold LS. This is consistent with the literature indicating that 
TRPV1 mediates heat but not cold nociception (Julius 2013). Thus, we conclude that 
TRPV1 contributes to the mechanical modality of LS that is masked by the endogenous 
NPY-Y1R axis.  
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Figure 2-7. TRPV1 antagonism attenuates Y1R-antagonist-induced 
reinstatement of inflammatory and neuropathic pain 
At 21 days after induction of CFA (A) or 28 days after CPxSx (B, C), drugs were 
administered by the i.t. route. AMG9810 (AMG, 10 nmol) attenuated BIBO3304-induced 
reinstatement of mechanical hypersensitivity in CFA (A) and CPxSx (B) mice, but not cold 
hypersensitivity in CPxSx (C) mice. A) Time course of mechanical thresholds at pre-
injection baseline, d3, d21 after CFA induction, and 30 and 60 min after the i.t. injection. 
B, C) Time course of mechanical (B) and cold (C) thresholds at pre-surgery baseline, d14, 
d28 after CpxSx surgery, and 30 and 60 min after the i.t. injection. Values represent mean 
± SEM. n=4-10. P < 0.05 (CpxSx vs sham group), P < 0.05 (Injury AMG+BIBO vs Injury 
BIBO group). Turkey’s post-hoc tests following repeated measures of 2-way ANOVA.  
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2.3.5  PKA-driven LS is TRPA1- and TRPV1-dependent 
After confirming the involvement of TRPA1/V1 channels in LS, we next sought to test 
the hypothesis that PKA-driven LS is TRPA1- and TRPV1-dependent. To test this 
hypothesis, 21 days after CFA, I intrathecally delivered TRPA1 or TRPV1 antagonists, 
HC030031 or AMG9810 respectively, together with the PKA activator 6Bnz. As illustrated 
in Figure 2-8, HC030031 abolished the ability of 6Bnz to reinstate mechanical 
hypersensitivity (Figure 2-8A, Group X Time, F2, 30 = 10.25; p = 0.0004), while AMG9810 
(30 nmol) attenuated the ability of 6Bnz to reinstate mechanical hypersensitivity (Figure 
2-8B, Group X Time, F3, 35 = 5.799; p = 0.0025). These data suggest that PKA-driven LS 
is mediated by TRPA1 and TRPV1 in the spinal cord in the setting of cutaneous 
inflammation.  
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Figure 2-8. PKA-driven LS is mediated by TRPA1 and TPRPV1 
At 21 days after induction of CFA, drugs were administered as a single i.t. injection. A) 
The10 µg HC030031 abolished 6Bnz (10 nmol)-induced reinstatement of mechanical 
hypersensitivity. n=9-12. P < 0.05 (HC030031+6Bnz vs 6Bnz group).  B) The 30 nmol 
AMG9810 attenuated 6Bnz-induced reinstatement of mechanical hypersensitivity. n=5-
12. P < 0.05 (AMG9810+6Bnz vs 6Bnz group). Values represent mean ± SEM. 
Bonferroni’s post-hoc tests following repeated measures of 2-way ANOVA.  
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2.3.6  PKA-driven LS is not AC1-dependent 
Up to this point, we have characterized an NMDAR-AC1-PKA-TRPA1/TRPV1 
signaling pathway that drives LS that is under the tonic inhibitory control of the NPY-Y1R 
axis. Both TRPA1 and TRPV1 are Ca2+ permeable cation channels, allowing Ca2+ influx 
into the cell upon activation. We posited that the influx of Ca2+ could cause further 
activation of the calcium-dependent enzyme AC1, forming a viscous positive feedback 
loop. To test this hypothesis that the PKA-TRP driven LS requires further activation of 
AC1, we used AC1 KO mice. At 28 days after CFA, I intrathecally delivered the PKA 
selective activator 6Bnz, at a dose that does not produce mechanical hypersensitivity in 
naïve mice, to AC1KO and WT mice. I found no significant difference of 6Bnz-induced 
reinstatement of mechanical hyperalgesia in AC1KO mice, as compared with WT control 
(Figure 2-9, P > 0.05). Therefore, we conclude that further activation of AC1 by PKA-TRP 
signaling pathway is not required for the maintenance of LS. Instead, we propose that, 
once PKA is activated during LS, it cannot be reversed with inhibition of the upstream 
AC1. 
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Figure 2-9. PKA-driven LS is not AC1-dependent 
At 28 days after induction of CFA, 6Bnz (10 nmol) was administered via i.t. injection in 
AC1KO and WT mice. The bar graph represents decrease in mechanical threshold, 30 
min after i.t. injection, plotted as percentage of pre-injection baseline. No significant 
difference was found between groups. n=7-9. Values represent mean ± SEM. Student’s t-
test was performed.  
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2.3.7  Epac1 and Epac2 contribute to LS, that is inhibited by the NPY-Y1R axis 
Two proteins comprise the Epac family: Epac1 (RapGef3, cAMP-GEF I) and Epac2 
(RapGef4, cAMP-GEF II). They catalyze GDP/GTP exchange in small G-proteins (de 
Rooij et al. 1998, Kawasaki et al. 1998) activating downstream signaling. An emerging 
literature indicates that both contribute to pain sensitization after injury (Griffin 2005, 
Hucho et al. 2005, Eijkelkamp et al. 2010, Eijkelkamp et al. 2013, Wang et al. 2013, Gu et 
al. 2016, Singhmar et al. 2016). Therefore, we tested the hypothesis that Epac is essential 
to LS.  Figure 2-10 illustrates my intrathecal approach to administer the highly selective 
Epac activator, 8cpt, at a dose (3 nmol) that does not produce mechanical hyperalgesia 
in sham mice. I found that this dose of 8cpt reinstated mechanical hyperalgesia in CFA 
day 21 mice (Figure 2-10 A, Group X Time; F3, 19 = 5.555; p = 0.0066). We conclude that 
during LS, Epac is in a silent, superactive state. The vulnerability of this system can be 
revealed with an Epac activator that is sufficient to override any inhibitory systems. 
We then sought to test the hypothesis that Epac-driven LS is under the inhibitory 
control of the NPY-Y1 axis. To distinguish Epac1 from Epac2 effects, I used a non-
selective Epac1/2 antagonist, HJC0197, a highly-selective Epac1 antagonists, ESI-09 and 
a highly-selectiveEpac2 antagonist HJC0350, generously provided by Dr. Jia Zhou (Chen 
et al. 2012, Almahariq et al. 2013, Chen et al. 2014). As illustrated in Figure 2-10B-D, I 
intrathecally administered these Epac antagonists together with the Y1 antagonist 
BIBO3304 in CFA day 21 mice. I found that both ESI-09 (Figure 2-10C, Group X Time; F3, 
45 = 5.033; p = 0.0043) and HJC0350 (Figure 2-10D, Group X Time; F3, 36 = 6.071; p = 
0.0019) attenuated BIBO3304-induced reinstatement of mechanical hyperalgesia. 
Consistent with these results, I found that the non-selective Epac antagonist HJC0197 
abolished BIBO3304-induced reinstatement of mechanical hyperalgesia (Figure 2-10B, 
Group X Time; F3, 39 = 5.749; p = 0.0023).  
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Thus, we propose that injury induces a superactive Epac system that is under the 
inhibitory control of NPY-Y1R axis during LS, and that both Epac1 and Epac2 contribute 
to LS that is inhibited by the endogenous NPY-Y1R axis. 
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Figure 2-10. Epac1 and Epac2 drive LS; silencing by the NPY-Y1R axis 
At 21 days after induction of CFA or sham, drugs were administered as a single i.t. 
injection. A) 8cpt (3 nmol) reinstated mechanical hyperalgesia in CFA but not sham day 
21 mice n=5-6. P < 0.05 (CFA vs sham group) P < 0.05 (CFA 8cpt vs sham 8cpt 
group). B) HJC0197 (10 µg) attenuated the BIBO3304 (BIBO, 5 µg)-induced reinstatement 
of mechanical hyperalgesia in CFA day 21 mice. n=6-14. P < 0.05 (HJC0197 + BIBO vs 
BIBO group). C) ESI-09 (10 µg) attenuated BIBO-induced reinstatement of mechanical 
hyperalgesia in CFA day 21 mice. n=10-14. P < 0.05 (ESI-09 + BIBO vs BIBO group). 
D) The HJC0350 (1 µg) attenuated BIBO-induced reinstatement of mechanical 
hyperalgesia in CFA day 21 mice. n=5-14. P < 0.05 (HJC0350 + BIBO vs BIBO group). 
Values represent mean ± SEM. Bonferroni’s post-hoc tests following repeated measures 
of 2-way ANOVA.  
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2.4  Discussion 
2.4.1  Tonic inhibition of LS by the NPY-Y1R axis is ligand-dependent 
During LS, when inhibitory controls fail, pain episodes ensue (Le Roy et al. 2011, 
Solway et al. 2011, Corder et al. 2013), indicating that not only the silenced sensitization 
is on-going, the endogenous inhibitory systems are also strengthened. Previous findings 
from our lab suggest that the long-lasting endogenous anti-hyperalgesia effect produced 
by the opioid system relies on the constitutive activity of µ-opioid receptor (Corder et al. 
2013). Both Y1R and µ-opioid receptor belong to Class I GPCRs, binding to Gαi/o. Thus, 
does the endogenous anti-hyperalgesia effect produced by NPY system also rely on 
constitutive activity of Y1R? 
We think that this is unlikely, for two reasons: 
1) An in vitro study suggested that, unlike the µ-opioid receptor, Y1R does not exhibit 
ligand-independent activation, due to the third intracellular loop that can stabilize 
the inactive state of the receptor (Chee et al. 2008). 
2) Studies from this chapter (Figure 2-6) and previously performed in NPY 
knockdown mice (Solway et al. 2011) suggested that the inhibitory control of LS 
by the NPY system is ligand-dependent.  
Therefore, our working hypothesis for future studies is that the tonic inhibition of injury-
induced LS by the NPY-Y1 axis relies on a long-lasting upregulation of spinal NPY release. 
Although we do not have direct evidence yet to confirm it, other lines of indirect evidence 
further supports this idea: 
1) An in vitro study suggested that although ligand binding leads to Y1R 
internalization, Y1R is targeted to a recycling instead of degradation pathway 
(Gicquiaux et al. 2002), indicating that ligand binding will not cause the 
downregulation of Y1R signaling.  
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2) During the hyperalgesia phase of peripheral inflammation or nerve injury, spinal 
NPY levels are elevated [Figure 4-1, (Wakisaka et al. 1992, Ji et al. 1994, Ma et 
al. 1998, Ossipov et al. 2002, Intondi et al. 2010, Wang et al. 2012)]. 
As discussed in Chapter 4, future studies will be performed to test the hypothesis 
that, during the pain remission phase in either the CpxSx or CFA model, our novel Y1R 
internalization assay will detect an upregulation of spinal NPY release induced by 
dorsal root stimulation in slices or paw stimulation in vivo. 
 
2.4.2  The contribution of AC1 to central sensitization and latent sensitization.  
Consistent with the literature (Wei et al. 2002), behavioral testing following CFA in 
Figure 2-2A shows that AC1KO mice developed less hypersensitivity compared with WT 
controls, indicating that AC1 mediates inflammatory hyperalgesia. Although AC1 KO 
reduces hypersensitivity after common peroneal nerve ligation (Xu et al. 2008), mediated 
by a supraspinal mechanism (Wang et al. 2011), by contrast, my data in a different model 
of nerve injury, CpxSx, indicate that, CS that develops in the spinal cord after nerve injury 
is not mediated by AC1 (Figure 2-2B and C). These disparate results can be explained by 
the different models of neuropathic pain, or different mechanisms in the brain and spinal 
cord. In vitro studies performed in spinal cord slices suggest that AC1 contributes to the 
LTP that is induced by high frequency stimulation (Wang et al. 2011). However, its 
contribution to nerve injury-induced plasticity is not well understood (Zhuo 2012). Thus, at 
the spinal cord level, no evidence suggests that CS following nerve injury is mediated by 
AC1.  
However, as shown in Figure 2-2 and 2-3, AC1 contributes to LS in the spinal cord 
after both inflammation and nerve injury. Because there is no evidence suggesting that 
AC1 mediates CS in the spinal cord after nerve injury (Wang et al. 2011), our data would 
suggest that CS and LS may not necessarily share the same signaling pathway. In 
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addition, using a hyperalgesic priming model, the Levine group demonstrated that 
generation of LS does not require production of the initial central sensitization (Parada et 
al. 2003). Therefore, LS may be a distinct molecular and cellular event from CS after injury. 
 
2.4.3  Modality-specific mediation of latent sensitization by TRPV1 and TRPA1.  
With only limited and controversial evidence suggesting its expression in astrocytes 
(Doly et al. 2004) and spinal neurons (Doly et al. 2004, Kim et al. 2012), TRPV1 expression 
in the spinal cord is widely considered to reflect expression in  the central pre-synaptic 
terminals of small C and Aδ nociceptors, as is TRPA1. (Szallasi et al. 1995, Caterina et 
al. 1997, Guo et al. 1999, Szallasi et al. 1999, Valtschanoff et al. 2001). Thus, spinal 
TRPA1/V1- mediated modulation of pain processing is most likely a pre-synaptic 
mechanism. TRPA1 and TRPV1 are extensively co-expressed in DRG neurons, with 97% 
TRPA1+ DRGs being detected with TRPV1 mRNA, and about 30% of TRPV1+ DRG 
neurons contain TRPA1 mRNA (Story et al. 2003). In addition, there is intensive interplay 
between the two channels: activation or sensitization of one channel could lead to 
activation of the other (Patil et al. 2010, Spahn et al. 2014). In periphery, TRPV1 is a 
thermal sensor, while TRPA1 senses cold. They mark distinct labelled lines for pain 
processing of different modalities. But at the spinal level, because of their intensive co-
localization and cross-excitation, the assumption is that labeled lines do not exist. 
However, interestingly, spinal viral delivery of shRNAs targeting TRPV1 (which 
silences TRPV1 expression) blunted only thermal hyperalgesia, but not cold allodynia after 
SNI (Hirai et al. 2014). Correspondingly, Figure 2-7 illustrates that spinal TRPV1 mediates 
mechanical but not cold LS after CpxSx. Based on these data, we speculate that labeled-
lines for specific modalities of somatosensory information remain intact at the spinal level 
in the setting of LS.  
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2.4.4  Conclusions and future studies 
In this Chapter, I identified and characterized novel molecular signaling pathways that 
drive LS in the spinal level after injury. I found that the NMDAR-AC1-PKA-TRPA1/V1 and 
NMDAR-AC1-Epac1/2 signaling pathways are silently superactive during LS: silent 
because of inhibitory control by the endogenous NPY-Y1 axis. Future studies are listed 
below: 
1) Although a previous publication from our lab has demonstrated endogenous opioid 
dependence-driven LS is mediated by NMDAR-Ca2+-AC1-cAMP signaling 
pathway (Corder et al. 2013). The contribution of cAMP has not been directly 
testing in the LS that is masked by the NPY-Y1 axis. To test this, cAMP ELISA 
assay could be performed in the L3-L5 spinal cord tissue from animals in pain 
remission. I predict that spinal delivery of Y1 antagonist BIBO3304 will lead to 
cAMP overshoot in latent sensitized mice. 
2) My data as shown in Figure 2-4A and 2-10A suggested that PKA and Epac are in 
a silent superactive state during LS, that an activator of them would lead to the 
reinstatement of pain. To test the hypothesis that this silent superactive state is 
caused by accumulation of inactive form of PKA and Eapc in the spinal cord, qPCR 
and ELISA/western blot can be performed in the L3-L5 spinal cord tissue to detect 
mRNA and protein levels at various stages after injury. I propose that injury will 
induce an increase of PKA and Epac levels in the spinal cord lasting through the 
remission phase.  
3) In the current study, although we speculate the TRPA1/V1-driven mechanism is 
exclusively pre-synaptic, we were not able to distinguish the pre- vs post-synaptic 
mechanisms, of the signaling pathway for the most part. To address this question, 
Y1-floxed mice with DRG or spinal delivery of adeno-associated virus (AAV) 
carrying cre could be used. With the site-specific knockout of the Y1R, we will be 
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able to distinguish the pre-synaptic terminal vs spinal neuron mediated 
mechanism.   
4) It is most likely that CFA and CpxSx models do not share the same mechanism for 
LS. The contribution of PKA and Epac has only been tested in the CFA model. The 
study needs to be repeated in the CpxSx model to determine whether the 
characterized NMDAR-AC1-PKA-TRPA1/V1 and NMDAR-AC1-Epac1/2 are 
universal signaling pathways driving both inflammation and nerve injury induced 
LS. 
5) My data do not eliminate the possibility that NMDAR could be downstream of PKA, 
forming a vicious cycle. Indeed, PKA phosphorylation of NMDAR contributes to the 
mechanism of central sensitization (Latremoliere et al. 2009). To test for this 
possibility, the NMDAR antagonist MK801 could be administered intrathecally 
together with the PKA activator 6Bnz in CFA day 21 or CpxSx day 28 mice to check 
whether MK801 attenuates or abolishes 6Bnz-induced hypersensitivity. 
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CHAPTER 3:  Neurochemical characterization of Y1-expressing interneurons in 
the dorsal horn of the spinal cord before and after peripheral nerve injury 
 
3.1  Introduction  
Peripheral nerve damage leads to a debilitating neuropathic pain syndrome that can 
persist for years, dramatically decreasing quality of life (Jensen et al. 2007).  Current 
analgesics are problematic due to insufficient efficacy and an unacceptable set of adverse 
effects, including addiction potential (Finnerup et al. 2015). These problems are due in 
part to our limited understanding of the neuronal circuitry within the superficial dorsal horn 
of the spinal cord that processes and transmits nociceptive information from the periphery 
to the brain. Although several distinct populations of excitatory interneurons have been 
identified, leading to the recognition of dorsally-directed microcircuits that are required for 
the behavioral expression of neuropathic pain (Wang et al. 2013, Braz et al. 2014, Duan 
et al. 2014, Gangadharan et al. 2015, Peirs et al. 2015), few of these subpopulations 
readily represent druggable targets for new pain therapeutics.  
A promising subpopulation of interneurons is the one that respond to the anti-
nociceptive actions of neuropeptide Y, namely, the NPY Y1 receptor (Y1R). Neuropathic 
pain is not only transiently inhibited by intrathecal administration of exogenous NPY 
(Intondi et al. 2008, Kuphal et al. 2008), but also tonically inhibited by NPY that is released 
within the dorsal horn. Thus, following conditional NPY knockdown in NPYtet/tet transgenic 
mice, previous work from our lab, now replicated by our work described in Chapter 2, 
demonstrated dramatic increases in the cold and mechanical hyperalgesia produced by 
nerve injury (Solway et al. 2011), and this could be mimicked with Y1R-selective 
antagonists (Intondi et al. 2008, Kuphal et al. 2008). Y1Rs are highly expressed at the 
dorsal horn of the spinal cord, including several populations of small interneurons located 
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throughout laminae I–III (Gibson et al. 1984, Ji et al. 1994, Brumovsky et al. 2002, 
Brumovsky et al. 2006, Brumovsky et al. 2007). Immunohistochemical studies have only 
localized a subpopulation of Y1R to the dendrites and somas of somatostatin-positive 
dorsal horn neurons (Zhang et al. 1999). Since this population expresses VGLUT1 and 
VGLUT2 (Todd et al. 2003, Hokfelt et al. 2007), Y1R-positive cells have been presumed 
to be glutamatergic, and thus excitatory (Brumovsky et al. 2007, Wiley et al. 2009).  
Indeed, our lab has proposed Y1-expressing cells as excitatory interneurons under an 
NPY-mediated inhibitory influence (Smith et al. 2007); however, rigorous co-labelling of 
Y1R with markers of excitatory neurons is lacking in the literature. Here, we characterized 
Y1R expression profile in the spinal cord, by quantification of co-labelling of Y1R with 
multiple markers of glia, nociceptors, excitatory and inhibitory interneurons.  Next, to better 
understand the possible plasticity of Y1R- expressing cells after nerve injury, we quantified 
Y1R co-labelling profiles with or without nerve injury. 
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3.2  Materials & Methods 
3.2.1  Animals 
     All animals were housed in a lighting (12-h light/dark cycle for rats and 14-h light/dark 
cycle for mice), temperature (68-72º F) and humidity-controlled room with food and water 
provided ad libitum. Animals were allowed a minimum of one week to habituate to the 
facility prior to their entrance into the study. All animal procedures were approved by the 
Institutional Animal Care and Use Committee of the University of Kentucky, followed the 
guidelines for the treatment of animals of the International Association for the Study of 
Pain, and conducted in full compliance with the Association for Assessment and 
Accreditation of Laboratory Animal Care. 
 
3.2.1.1  Rats 
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 
200-250 g at the time of surgery or injection were used in the study. They were housed 2 
per cage. 
 
3.2.1.2  Npy1r-EGFP mice 
The Npy1r-EGFP mouse line was generated by bacterial artificial chromosome (BAC)-
based transgenic technology (GENSAT, New York, NY). A soluble enhanced green 
fluorescence protein (EGFP) reporter was inserted immediately upstream of the coding 
sequence of the Npy1r gene on chromosome 8 (Gong et al. 2003). The mouse line was 
maintained in our facility using a sib-mating breeding strategy (wildtype female x 
hemizygous transgenic male littermate or reciprocal mating) onto a mixed FVB/N and 
Swiss Webster background by Renee Donahue. Genotype was confirmed by an ear-
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puncture and then PCR. All mice were housed maximum 4 per cage with same-sex 
littermates. 
 
3.2.2  Animal Models of Persistent Pain 
3.2.2.1  Complete Freund’s Adjuvant (CFA) model of inflammatory pain  
 Rats were injected subcutaneously with 100 µl CFA (1mg/ml, Sigma-Aldrich, St. Louis, 
MO) into the midplantar region of the left hindpaw, under anesthesia with isoflurane (5% 
for induction, and 3% for maintenance), with a 27G needle. 
 
3.2.2.2  Spared Nerve Injury (SNI) model of neuropathic pain 
Please refer to section 2.2.3.2. Absorbable 5-0 sutures (Ethicon) were used to suture 
the muscle in rats. 
 
3.2.3  Behavioral testing for mechanical threshold  
 Rats were acclimated to their testing cubicles (transparent Plexiglass boxes placed on 
a raised metal mesh grid) for at least 60 min. To evaluate sensitivity to a non-noxious 
mechanical stimulus, we used an incremental series of 8 von Frey filaments (Stoelting, 
Inc, Wood Dale, IL) of logarithmic stiffness (0.6-10 grams).  The 50% withdrawal threshold 
was determined using the up-down method (Chaplan et al. 1994).  Each filament was 
applied perpendicular to the central (for CFA model), or lateral (innervated by the sural 
branch of the sciatic nerve, for SNI model) hindpaw surface with sufficient force to cause 
a slight bending of the filament. A positive response was defined by a rapid withdrawal of 
the paw within 5 seconds, as silently counted by the experimenter. 
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3.2.4  Intrathecal (i.t.) NPY administration 
 A 30 μg dose of NPY (Anaspec, Fremont, CA) was administered to rats via a direct 
spinal intrathecal injection in a volume of 10 μl using a 25 μl Hamilton microsyringe 
attached to a 27-gauge disposable sterile needle under isoflurane anesthesia (5% 
induction; 3% maintenance). The needle was inserted into the subarachnoid space 
through the intervertebral foramen. A tail flick response and/or aspiration of CSF was used 
as verification of correct placement of the needle.  
 
3.2.5  Antibody characterization and IB4 specificity 
Detailed information of primary antibodies, including immunogen, source, catalog number, 
RRID, host and concentration used in this Chapter is summarized in Table 3-1.  
 Y1R: Two Y1R antibody were used: One was a generous gift from J. H. Urban 
(AB_2314975) (Wolak et al. 2003), and the other was from Neuromics (RA24506). 
Both antibodies were made in rabbit with the same immunogen. Dr. Urban 
determined the specificity of this antibody using preimmune sera and 
preabsorption of the antibody with the antigen in western blot and 
immunohistochemistry (Wolak et al. 2003). These two Y1R antibodies provide 
identical staining patterns in the rat spinal cord as compared to previous reports 
using another well-characterized, but discontinued Y1R antibody from CURE at 
the University of California, Los Angeles (Zhang et al. 1994). However, these Y1R 
antibodies failed to stain the mouse spinal cord. 
 NeuN: First described and characterized by Mullen et al.,  (Mullen et al. 1992), this 
AF488 conjugated NeuN antibody (AB_2149209) has been widely used to label 
most neuronal nuclei in the nervous system of vertebrates for over 20 years. The 
antibody has been show to cross-react with the RNA splicing factor Fox-3. 
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However, Fox-3 and NeuN almost always colocalize in the spinal cord, so the 
cross-reaction does not hinder the ability of the antibody to label neurons (Kim et 
al. 2009). 
 Ox-42: In our hands, this Ox-42 antibody (AB_1603214) only stains cells with the 
classic morphology of microglia in the rat spinal cord (Figure 3-1). 
 GFAP: According to the manufacturer, this GFAP antibody (AB_477010) stains a 
single band of ~50 kDa molecular weight in Western blot of rat and mouse brain 
lysates. In our hands, it only stains cells with the classic morphology of astrocytes 
in the rat spinal cord (Figure 3-1). 
 CGRP: According to the manufacturer, this CGRP antibody (AB_2314158) cross-
reacts 100% with rat CGRP, and 0% with rat amylin and calcitonin as confirmed 
by radioimmunoassay. Preabsorption with CGRP peptide abolishes its staining in 
rat spinal cord and DRG (Brumovsky et al. 2002).  
 IB4-biotin: According to the manufacturer, the specificity of this biotin-conjugated 
IB4 (AB_2313663) was validated by preincubating in a 0.1 M solution of D-
galactose and N-acetylgalactosamine. Specific lectin reactions were eliminated 
following these procedures. 
 Substance P (SP): Characterized by our collaborator, Dr. Marvizon in UCLA 
(Marvizon et al. 2009), this SP antibody (AB_661439) co-labels well with another 
well characterized SP antibody used in the same paper. In addition, the staining 
pattern with this antibody in the rat dorsal horn agrees with literature (De Biasi et 
al. 1988). 
 Tlx3: This Tlx3 antibody (AB_2532145) was a generous gift from Carmen 
Birchmeier (Muller et al. 2005). It does not stain the spinal cord of adult conditional 
Tlx3 knockout mice (Xu et al. 2013). It has been used by many high-profile 
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publications, and our staining pattern of Tlx3 in the spinal cord of mice and rat are 
consistent with these publications (Cheng et al. 2005, Xu et al. 2008, Xu et al. 
2013). 
 Pax-2: According to the manufacturer, this Pax-2 antibody (AB_10889828) stains 
a single band of ~40 kDa molecular weight in western blot of COLO 205 human 
colorectal adenocarcinoma cell lysates. In direct ELISAs, less than 5% cross-
reactivity with recombinant human (rh) Pax3, rhPax4, rhPax5, rhPax6, and 
rhPax7 is observed. Human and mouse Pax2 share 98% aa sequence identity.  
 Calbindin: According to the manufacturer, this calbindin (AB_476894) antibody 
does not react with other members of the EF-hand family, such as calbindin-D-9K, 
calretinin, myosin light chain, parvalbumin, S-100a, S-100b, S-100A2 (S100L) and 
S-100A6 (calcyclin). It stains a single band of ~26 kDa molecular weight in western 
blot of extract of rat leg muscle. Species cross-reactivity has been observed with 
rat and mouse.  
 Calretinin: According to the manufacturer, this calretinin (AB_10000342) antibody 
does not stain the brain of calretinin knockout mice. 
 PKCγ: This PKCγ antibody was a generous gift from Dr. Allan Basbaum. In our 
hands, the staining pattern in rat spinal cord agrees with the literature (Neumann 
et al. 2008). 
 Somatostatin (SST): This SST antibody (AB_383280) has been used intensively 
in rat neuronal tissue (Corteen et al. 2011). In our hands, the staining pattern in rat 
spinal cord agrees with the literature.  
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Table 3-1. Primary antibodies and IB4 used in Chapter 3 
 
 
Primary 
antibody 
 
Immunogen 
 
Source 
 
Catalog No., 
RRID 
 
Host 
 
Concentration 
Y1R Synthetic peptide sequence corresponding to 
amino acids 356-382 of the rat NPY Y1 receptor 
J. H. Urban N/A, 
AB_2314975 
Rabbit 
Polyclonal 
1:500 
Y1R Same as above Neuromics RA24506, 
N/A 
Rabbit 
Polyclonal 
1:1,000 
AF-488 
NeuN 
Neuron specific nuclear protein clone  mAb A60 EMD 
Millipore 
MAB377X,  
AB_2149209 
Mouse 
Monoclonal 
1:200 
Ox-42 Rat peritoneal macrophages Abcam Ab78457, 
AB_1603214 
Mouse 
Monoclonal 
1:400 
GFAP Purified GFAP from pig spinal cord Sigma-
Aldrich 
G3893, 
AB_477010 
Mouse 
Monoclonal 
1:3,000 
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Table 3-1. Primary antibodies and IB4 used in Chapter 3 (Continued) 
 
 
Primary 
antibody 
 
Immunogen 
 
Source 
 
Catalog No., 
RRID 
 
Host 
 
Concentration 
CGRP Synthetic CGRP peptide Peninsula 
Laboratories 
T-5027, 
AB_2314158 
Guinea pig 
Polyclonal 
1:1,000 
Biotin-IB4 N/A Sigma-Aldrich L2140, 
AB_2313663 
N/A 1:100 
SP A peptide corresponding to full length 
mature of Substance P of human origin 
Santa Cruz SC-9758, 
AB_661439 
Goat 
Polyclonal 
1:1,000 
Tlx3 Bacteria BL21(DE3)pLysS derived mouse 
recombinant Tlx-3 
Carmen 
Birchmeier 
AB_2532145 Guinea pig, 
Polyconal 
1:10,000 
Pax-2 E. coli-derived recombinant human Pax2 R&D systems AF3364, 
AB_10889828 
Goat 
Polyclonal 
1:1,000 
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Table 3-1. Primary antibodies and IB4 used in Chapter 3 (Continued) 
 
 
Primary 
antibody 
 
Immunogen 
 
Source 
 
Catalog No., 
RRID 
 
Host 
 
Concentration 
Calbindin Bovine kidney calbindin-D Sigma-Aldrich C9848, 
AB_476894 
Mouse 
Monoclonal 
1:1,000 
Calretinin human recombinant calretinin Swant CG1, 
AB_10000342 
Goat 1:5,000 
PKCγ N/A Strategic 
BioSolutions 
N/A Guinea pig 1:10,000 
SST Somatostatin conjugated to a 
protein carrier 
GeneTex GTX71935 
AB_383280 
Mouse 
Monoclonal 
1:100 
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3.2.6  Immunohistochemistry 
To help with identification of Y1R-expressing spinal neurons in the spinal cord, two 
successive intrathecal injections of 30 µg of NPY were performed in naïve rats, separated 
by 1h. This method provides us clearer looking Y1R cells, possibly by increasing Y1R 
expression.  
Rats were perfused 1h after the second injection (for Y1R co-labelling studies with 
interneuron markers only). Rats were deeply anesthetized with isoflurane, and perfused 
with 200ml 0.1 M PBS containing heparin (10,000 USP units/L) followed by 200 ml 10% 
phosphate buffered formalin (Fisher Scientific, Pittsburgh, PA).  Lumbar spinal cords were 
dissected and post-fixed in 10% formalin for 4h, cryoprotected in 30% sucrose overnight, 
and sectioned transversely at 35-60 μm (L4-L6) on a freezing microtome. The sections 
were washed 3 times in 0.1 M PBS and then pretreated with blocking solution [3% normal 
goat/donkey serum (Gemini Bio Products, Broderick, CA) and 0.3% Triton X-100 (Sigma-
Aldrich, St Louis, MO) in 0.1 M PBS] for 1 hour. Sections were incubated overnight at 
room temperature in antibody dilution solution (1% normal goat/donkey serum and 0.3% 
Triton X-100 in 0.1 M PBS) with combination of primary antibodies for the co-labelling 
studies (Table 3-1). Sections were then washed, incubated in antibody dilution solution 
with combination of secondary antibodies (Table 3-2) for 1.5h at room temperature, 
washed again, mounted onto Superfrost Plus slides, air dried for 45 min, and mounted 
using Prolong Gold with DAPI mounting medium (Molecular Probes, Eugene, OR). 
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Table 3-2. Secondary antibodies used in Chapter 3 
 
Secondary antibody 
 
 
Source 
 
Catalog No.,  
RRID 
 
 
Concentration 
Alexa 568-conjugated 
goat anti-rabbit 
Invitrogen A-11036, 
AB_143011 
1:1000 
Alexa 568-conjugated 
donkey anti-rabbit 
Invitrogen A-10042, 
AB_2534017 
1:1000 
Alexa 488-conjugated 
goat anti-guinea pig 
Invitrogen A-11073, 
AB_2534117 
1:1000 
Alexa 488-conjugated 
goat anti-mouse 
Invitrogen A-11029, 
AB_2534088 
1:1000 
Alexa 488-conjugated 
donkey anti-goat 
Invitrogen A-11055, 
AB_2534102 
1:1000 
Alexa 647-conjugated 
donkey anti-mouse 
Invitrogen A-31571, 
AB_162542 
1:1000 
Alexa 633-conjugated 
donkey anti-goat 
Invitrogen A-21082, 
AB_10562400 
1:1000 
Alexa 488-conjugated 
donkey anti-guinea 
pig 
Jackson 
ImmunoResearch 
706545148, 
AB_2340472 
1:800 
Streptavidin-DyLight 
488 
Vector 
Laboratories 
SP-4488, 
AB_2532066 
1:200 
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3.2.7  Confocal microscopy and image processing  
[Texts inside {} in this subsection have been extracted from the previously published 
(Taylor et al. 2014).] 
In Figures 3-1 and 3-4, {confocal images were acquired using a Zeiss LSM 710 
confocal microscope by Dr. Juan Carlos Marvizon’s lab at Los Angeles, CA (Carl Zeiss, 
Inc., Thornwood, NY). A 63x oil immersion objective (numerical aperture 1.4) was used 
to take high magnification images from transverse and sagittal lumbar spinal cord 
sections. Laser excitation lines and emission windows for the different fluorophores 
were: Alexa Fluor 488 - excitation 488 nm (Ar laser), emission 500–540 nm; Alexa Fluor 
568 - excitation 561 nm (diode laser), emission 580–630 nm; Alexa Fluor 633 - excitation 
633 nm (HeNe laser), emission 650–720 nm. The pinhole was 1.0 Airy unit, and its 
actual width was set to that value for each objective and fluorophore. Images were 
acquired as confocal stacks of sections of 1024 × 1024 pixels. The separation between 
optical sections was determined by the microscope software by applying the Nyquist 
formula to the objective used; it was 6.66 μm for the 10x objective, 1.02 μm for the 20x 
objective and 0.43 μm for the 63x objective. Imaris 6.1.5 (Bitplane AG, Zurich, 
Switzerland) was used to crop the images in three dimensions and to generate a two-
dimension projection picture. This picture was imported into Adobe Photoshop 5.5 
(Adobe Systems Inc., Mountain View, CA), which was used to assemble the multi-panel 
figures.} 
In Figures 3-2, 3-6, 3-8, and 3-10, confocal images were acquired with a Leica ABOS 
TCS SP5 inverted laser scanning confocal microscope located in the Light Microscopy 
Core at the University of Kentucky Medical Center. The microscope is a Leica DMI 6000 
with LAS AF 2.7.2.9586 software.  An 63x or 100X oil immersion objective (numerical 
aperture 1.4) was used. Laser excitation lines and emission windows for the different 
fluorophores were: Alexa Fluor 488 - excitation 488 nm (Ar laser), emission 505–555 nm; 
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Alexa Fluor 568 - excitation 543 nm (diode laser), emission 565–615 nm; Alexa Fluor 633- 
excitation 633 nm (HeNe laser), emission 635-685 nm; DAPI - excitation 405 nm (HeNe 
laser), emission 435-485 nm. Line averaging (1-32) was used to decrease signal to noise 
ratio. Images were taken at the medial (transected-nerve innervation territory) and central-
lateral aspects (sural innervation territory) of the transverse section of Lamina II of the 
spinal cord. Adobe Illustrator CS6 (Adobe Systems Inc., Mountain View, CA) was used to 
assemble the multi-panel figures.  
 
3.2.8  Quantification of Co-localization  
[Texts inside {} in this subsection have been extracted from the previously published 
(Taylor et al. 2014).] 
In Figure 3-3: {in dorsal horn images, our goal was to determine whether the targets 
of the antibodies (for example, the Y1R and a neuropeptide) were present in the same 
sub-cellular compartments of neurons: presynaptic terminals, axons or dendrites. This 
was assumed to be the case when the two labels were present in the tissue with enough 
proximity that they cannot be resolved optically {Hibbs, 2006 #580}. This type of co-
localization was measured using the Co-localization module of the Imaris software, 
which analyzes two-channel stacks of confocal sections by measuring the intensity of 
each label in each voxel. In triple-label images, co-localization was measured in all the 
three possible two-channel combinations. The extent of co-localization of two labels was 
measured as the Pearson correlation coefficient of the intensity of the labels in the 
voxels in a confocal stack. Voxels belonging to the background were excluded from the 
comparison by limiting the measures to voxels with intensities higher than 20 or 30, in 
the scale of 0–255. The Pearson coefficient indicates the extent to which the intensities 
of the two labels increase in parallel with each other in the same voxels. It varies 
between +1 and −1, with positive values indicating a direct correlation, negative values 
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indicating an inverse correlation, and values near 0 indicating no correlation. Based on 
the results obtained with negative and positive co-localization controls in a previous 
study (Marvizon et al., 2009), Pearson coefficients below 0.1 were interpreted as no co-
localization, and Pearson coefficients above 0.5 as near-maximal co-localization. In 
DRG images, our goal was to determine whether the two labels were present in the 
same neuronal body regardless of their proximity. It was measured by visually counting 
neuronal profiles with each of the labels and with the two labels together, and then 
calculating the percentage of double-labelled profiles relative to each of the single-
labelled profiles.} 
In Figures 3-5, 3-7, 3-9 and 3-10, medial and central-lateral regions of Lamina II from 
a randomly-selected side (naïve), or both ipsi- and contralateral side (SNI) of the dorsal 
horn of a section were imaged and quantified.  Cells are counted as a marker-positive cell 
with the facilitation of the nuclear stain, DAPI. The experimenter (Weisi Fu) was blinded 
to ipsi- versus contralateral side. Co-labelling was counted manually by WF. 3 slices per 
rat were analyzed, and n=3 rats per antibody pair is reported. The blinding code was 
revealed to WF by imaging the ventral horn to identify the contralateral side marker (a cut 
made before slicing the cord) after quantification. 
 
 
3.2.9  Statistical Analysis  
Data were analyzed using Prism software (GraphPad, San Diego CA). In Figure 3-3, 
data were analyzed by two-way analysis of variance (ANOVA) followed with Holm-Sidak's 
post-hoc test. In Figures 3-5, 3-7, 3-9 and 3-10, data were analyzed by one-way ANOVA 
followed with Tukey's post-hoc test. All data are expressed as mean ± SEM. Statistical 
significance was set at P < 0.05.  
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3.3  Results 
3.3.1  Y1R is expressed in the spinal neurons but not in the glia 
To better understand the Y1R-mediated pain inhibitory circuitry in the superficial dorsal 
horn of the spinal cord, we first asked whether Y1R is present in glia. I co-stained Y1R 
with a neuronal marker NeuN, a microglial marker Ox-42, and an astrocytic marker glial 
fibrillary acidic protein (GFAP) in the transverse spinal cord sections, and assessed co-
labelling of immunoreactivity in laminae I-III using high magnification confocal microscopy 
(Figure 3-1). I found that all Y1R-expressing cells in Lamina II are NeuN positive in naïve 
rats (Figure 3-1A). I could not find co-labelling of Y1R immunoreactivity with either Ox-42 
(Figure 3-1D) or GFAP (Figure 3-1G). We then asked whether inflammation or nerve injury 
could induce Y1R expression in glia. By performing the co-labelling study using spinal 
cord sections from CFA day3 and SNI day7 rats, we found that neither inflammation 
(Figure 3-1B, E, H) nor nerve injury (Figure 3-1C, F, I) induced Y1R immunoreactivity in 
glia at the time points we tested. Our data suggest that Y1R is not expressed in spinal 
glia, and therefore endogenous NPY directly activates Y1R in neurons, not glia, to exert 
its anti-hyperalgesic actions in the superficial dorsal horn of the spinal cord. 
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Figure 3-1. Y1R is expressed in spinal neurons but not glia. 
Transverse sections of lumbar spinal cord (L4–L6) were co-labelled with antibodies 
against Y1R, and NeuN (A-C), Ox-42 (D-F) or GFAP(G-I). Each image consists of a 
single confocal section taken with a 63x objective at the middle of the histological 
section. Dorsal side is up. A, D, G) spinal cord sections from naïve rats; B, E, H) spinal 
cord sections from CFA day3 rats; C, F, I) spinal cord sections from SNI day7 rats. 
Arrows indicate instances of Y1R co-labelling. Scale bar: 20 µm. Experiments were 
performed by Weisi Fu at University of Kentucky. Pictures were taken by Dr. 
Marvizon’s Group at University of California, Los Angeles. 
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3.3.2  Presence of Y1R in primary afferent terminals 
 [Texts in this subsection 3.3.2 have been extracted from the previously published 
(Taylor et al. 2014).] 
Next, we investigated what population of primary afferent terminals is Y1R present in 
the superficial lamina of dorsal horn. Double-labelling of DRG sections with antibodies 
against CGRP and Y1R suggested that about 75% of Y1R-positive DRG cells were also 
CGRP-positive, and 50% of CGRP-positive cells were Y1R-positive. In contrast, less than 
20% of IB4-positive cells expressed Y1R, although about 40% of Y1R cells stained for 
IB4. In transverse spinal cord sections under low magnification, Y1R staining appeared 
as a narrow band that overlapped both the area stained by CGRP and the area stained 
by IB4, which largely corresponded to different laminae of the dorsal horn (Taylor et al. 
2014). To determine whether Y1R was present in primary afferents that contained CGRP, 
SP or IB4, we assessed co-localization of immunoreactivity in laminae I and II of sagittal 
spinal cord sections using high magnification confocal microscopy (Figure 3-2). As 
established previously (Lawson 1995, Marvizon et al. 2009), we observed substantial co-
localization of CGRP and SP immunoreactivity in fibers and puncta (Figure 3-2A). Y1R 
immunoreactivity was largely restricted to lamina II neurons and their dendrites. We could 
not find co-localization of Y1R immunoreactivity with either CGRP- and SP-containing 
fibers, although we occasionally observed them to be in close proximity. SP 
immunoreactivity and IB4 staining did not co-localize with each other or with Y1R (Figure 
3-2B). To confirm these qualitative observations, we quantified co-localization in confocal 
images similar to those shown in Figure 3-2. As shown in Figure 3-3, Pearson coefficients 
for CGRP-SP were above 0.5, indicating a high level of co-localization. In contrast, 
Pearson coefficients for IB4-SP, Y1R-CGRP, Y1R-SP and Y1R-IB4 were close to 0.0, 
indicating that Y1R immunoreactivity is not robust in fibers that stain for CGRP, SP, or 
IB4. 
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Figure 3-2. Localization of Y1R relative to substance P, CGRP and IB4 staining 
of the central terminals of primary afferents in the rat superficial dorsal horn  
Sagittal sections from the lumbar spinal cord (L4–L6) were labelled with antibodies 
against substance P (SP), CGRP or the Y1R, or with isolectin B4-biotin (IB4). 
Confocal images were taken with a 63x objective from the laminae I-II. Optical 
section separation is 0.44 μm. Dorsal side is up. Arrows indicate instances of SP / 
CGRP co-localization. Asterisks indicate the cell bodies of Y1R neurons. A) 
Substance P, CGRP and Y1R immunoreactivities; 7 optical sections. B) Substance 
P immunoreactivity, IB4 staining and Y1R immunoreactivity; 4 optical sections. [This 
figure is published (Taylor et al. 2014).] (Experiments were designed by Dr. Bradley 
Taylor, Dr. Juan Carlos Marvizon and Weisi Fu. Animal work and 
immunohistochemistry experiments were performed by Weisi Fu at University of 
Kentucky. Pictures were taken and analyzed by Dr. Marvizon’s Group at University 
of California, Los Angeles).  
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Figure 3-3. Quantification of co-localization of Y1R with CGRP, IB4 and SP  
Co-localization of the indicated label pairs was measured with Imaris Co-localization 
as the Pearson correlation coefficient in all voxels in a confocal stack above 
intensity thresholds of 20 or 30 (in the scale of 0–255). ANOVA, p < 0.0001, F4,20 = 
43.02, ***p < 0.001 compared to CGRP - SP (Holm-Sidak's post-hoc test). [This 
figure is published (Taylor et al. 2014).] (Experiments were designed by Dr. Bradley 
Taylor, Dr. Juan Carlos Marvizon and Weisi Fu. Animal work and 
immunohistochemistry experiments were performed by Weisi Fu at University of 
Kentucky. Pictures were taken and analyzed by Dr. Marvizon’s Group at University 
of California, Los Angeles). 
 
 
 
84 
 
 
3.3.3  Y1R is expressed in excitatory but not inhibitory spinal interneurons  
Having demonstrated that Y1R is predominantly expressed on spinal neurons (Figure 
3-1), we next sought to characterize the Y1R-expressing dorsal horn neurons. Neuronal 
phenotypes can be classified based upon the transcription factors that regulate the 
development of their lineage (Gross et al. 2002, Cheng et al. 2004, Cheng et al. 2005, Xu 
et al. 2008, Del Barrio et al. 2013, Wildner et al. 2013), such as Tlx3 and Pax2. Tlx3 is a 
transcription factor that determines the fate of spinal interneurons to be glutamatergic over 
GABAergic during early embryonic stage, while Pax2 directs interneurons to a GABAergic 
fate. Tlx3 expression in spinal neurons from an adult animal is principally restricted in 
laminae I and II, with some week expression in lamina III. These neurons are considered 
excitatory local interneurons. In contrast, Pax2 is more broadly expressed in the mature 
dorsal and ventral spinal cord, and it marks most GABAergic neurons in the dorsal horn 
(Del Barrio et al. 2013). 
As illustrated in Figure 3-4, double-labelling of L4-L6 lumbar spinal cord sections from 
naïve rats with antibodies against Y1R and Tlx3 showed that almost all Y1R-expressing 
spinal neurons in lamina II also expressed Tlx3 (Figure 3-4A). In contrast, few Y1R-
positive spinal neurons were labelled with Pax2 (Figure 3-4B). A quantification analysis of 
confocal images was performed to determine the Y1R co-labelling profile. As illustrated in 
Figure 3-5, 96.96 ± 0.86% of Y1R-positive neurons were also Tlx3-positive, while about 
20% of Tlx3-positive cells expressed Y1R (Figure 3-5A). In contrast, only 2.42 ± 1.21% of 
Y1R-positive cells expressed Pax2, while less than 2% of Pax2-postive cells stained for 
Y1R (Figure 3-5B). I observed no difference of the co-labelling pattern between medial 
and central-lateral aspects of the transverse section of the spinal cord (P > 0.05). My 
results indicate that Y1R-expressing cells represent 20% of Lamina II excitatory 
interneurons that predominantly overlaps with the Tlx3. 
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To confirm these results, I labelled the lumbar L4-L6 spinal cord sections of Npy1r-
EGFP mice with antibodies against Tlx3 or Pax2. I found that Npy1r-EGFP cells were 
mostly distributed in Laminae I-III, concentrated in lamina II. This is consistent with my 
antibody staining pattern of Y1R in rats. As illustrated in Figure 3-6, consistent with my 
findings in rats, most, if not all, green fluorescence cells in lamina II showed Tlx3 (Figure 
3-6A), but not Pax2 immunoreactivity (Figure 3-6B). I observed a small proportion (5%) of 
EGFP-expressing cells that lacked Tlx3 immunoreactivity. These cells were located at the 
border of Laminae II and III, or in Lamina III. This finding agrees with literature that Tlx3 
expression is mostly restricted to laminae I-II. 
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Figure 3-4. Spinal Y1R expression was expressed in excitatory but not 
inhibitory interneurons.   
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve rats were co-
labelled with antibody against Y1R, and antibodies against Tlx3 or Pax2. Each image 
consists of a single confocal section taken with a 100x objective at the middle of the 
histological section from Lamina II. Dorsal side is up. Images in B and D are zoomed in 
from the white square boxes shown in A and C respectively. A, B) Y1R and Tlx3 
immunoreactivities; C, D) Y1R and Pax2 immunoreactivities. Arrowheads indicate 
instances of Y1R colabelling. Scale bars: 10 µm.  
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Figure 3-5. Quantification of the effect of SNI on co-labelling of Y1R with Tlx3 
and Pax2 in lamina II  
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve and SNI day 14 
rats were double labelled as indicated. Images were obtained from lamina II of dorsal 
horn. Two images were taken per side per section, one from the medial and the other 
from the central-lateral aspect. (Please refer to Figure 1-3 for sciatic nerve innervation 
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zones in the spinal cord.) Co-labelling was measured by calculating the percentage 
of double-labelled profiles relative to each of the single-labelled profiles. 
A) Quantification of co-labelling of Y1R and Tlx3; B) Quantification of co-labelling of Y1R 
and Pax 2. 3 sections were analysed for each animal. n= 3. Values represent mean ± 
SEM. ★p < 0.05 vs contralateral side; #p < 0.05 vs naïve group. Turkey post-hoc test is 
following one-way ANOVA. 
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Figure 3-6. Y1R co-labelling with interneuron markers in Npy1r-EGFP mice 
Transverse sections of lumbar spinal cord (L4–L6) taken from Npy1r-EGFP mice were 
labelled with antibodies against Tlx3, Pax2 or calretinin (Calr). Each image consists of 
a single confocal section taken with a 63x objective at the middle of the histological 
section from superficial dorsal horn. Dorsal side is up. A) Tlx3 immunoreactivity; B) 
Pax2 immunoreactivity; C) Calretinin immunoreactivity. Arrowheads indicate instances 
of Y1R-EGFP colabelling. Scale bars: 10 µm.  
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3.3.4  Nerve injury changes the profile of Y1R co-labelling with excitatory and inhibitory 
neuronal markers. 
Next, I investigated whether nerve injury changes the Y1R co-labelling profile with 
either the excitatory neuronal marker Tlx3 or the inhibitory neuronal marker Pax-2. The 
L4-L6 lumbar spinal cord tissue from rats 14 days after SNI surgery was processed for 
quantification of double-labelling. As illustrated in Figure 3-7, I found that nerve injury did 
not change the number of Y1R-expressing cells in the spinal cord, neither in the 
innervation area of the transected sciatic nerves (medial), nor in that of the spared sural 
nerve (central-lateral). Please refer to Figure 1-3 for sciatic nerve innervation zones in 
the spinal cord. My finding agrees with the literature that dorsal rhizotomy or sciatic nerve 
constriction have little effect on Y1R-like immunoreactivity (Y1R-LI) in the dorsal horn 
(Brumovsky et al. 2002, Brumovsky et al. 2004). 
As illustrated in Figure 3-5, SNI decreased the percentage of Y1R cells that co-
expressed Tlx3 from 98.96% to 77.37% in the central-lateral aspect of the spinal cord 
ipsilateral side to nerve injury (F2,6 = 19.95, P = 0.0022). This led to an overall decrease of 
the percentage of Y1R cells that co-expressed Tlx3 in both medial and central-lateral 
aspect of the ipsilateral side (F2,6 = 6.75, P = 0.0292, Figure 3-5A). In contrast, the 
percentage of Y1R cells that co-expressed Tlx3 in medial aspect of the ipsilateral side was 
not changed by nerve injury (P > 0.05). In addition, SNI did not change the percentage of 
Tlx3 cells that co-expressed Y1R (P > 0.05).  
The Pax2 data of Figure 3-5B suggests that SNI led to a shift of the percentage of 
Y1R- cells that co-expressed Pax2 in the sural nerve innervation area from contralateral 
to ipsilateral side (F2,6 = 6.16, P = 0.0351). I observed no changes in the percentage of 
Y1R cells that co-expressed pax2 in medial aspect, nor the percentage of Pax2 cells that 
co-expressed Y1R after nerve injury.  
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Figure 3-7. Nerve injury does not change the number of Y1R-expressing neurons 
Data were pooled from quantification studies in Figure 3-7 and 3-11. Y1R-positive 
cells were counted per image taken. n= 9. Values represent mean ± SEM. Turkey’s post-
hoc test is following one-way ANOVA. 
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3.3.5  Y1R-expressing spinal interneurons are heterogeneous 
Having demonstrated that Y1R is predominantly expressed in excitatory local 
interneurons in the superficial dorsal horn, we next sought to further characterize the 
identity of Y1R-expressing dorsal horn interneurons. Please refer to section 1.2.4 for the 
introduction of representative populations of excitatory spinal interneurons. As illustrated 
in Figure 3-8, double-labelling of L4-L6 lumbar spinal cord sections from naïve rats with 
antibodies against Y1R and spinal interneuron markers calbindin, calretinin, PKCγ or 
somatostatin showed that Y1R was extensively co-labelled with calbindin (Figure 3-8A, 
B), and to a somewhat lesser extent with calretinin (Figure 3-8C, D), but not with PKCγ 
(Figure 3-8E, F). Consistent with literature (Zhang et al. 1999), Y1R also co-labelled with 
somatostatin (Figure 3-8G). In Npy1r-EGFP mice, I found that Y1R co-labelled with 
calretinin (Figure 3-6C), consistent with my findings using the Y1R antibody in rats. 
A quantification analysis of confocal images was performed to determine the Y1R co-
labelling profile with calbindin and calretinin. As illustrated in Figure 3-9, 36.06 ± 5.41% 
of Y1R-positive neurons were also calbindin-positive, and 36.15 ± 1.89% of calbindin-
positive cells expressed Y1R (Figure 3-9A); while 18.02 ± 1.65% of Y1R-positive neurons 
co-expressed calretinin, and 17.88 ± 3.33% of calretinin-positive cells co-expressed Y1R 
(Figure 3-9B).  
Calbindin and calretinin are homologous calcium-binding proteins. Both are found 
abundant in laminae I-II of spinal cord in rats (Ren et al. 1994). However, whether they 
co-localize in superficial laminae of the spinal cord is controversial (Rogers et al. 1990, 
Ren et al. 1994). To address this question, I performed a double staining study with 
antibodies against calretinin and calbindin. As shown in Figure 3-12, I found that 22.09 ± 
3.27% of calbindin co-stained with calretinin, and 24.34 ± 5.52% of calretinin cells also 
expressed calbindin in Laminae I-II.  
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My results suggest that the Y1R-expressing excitatory interneurons are 
heterogeneous and can be further divided into subpopulations with different neuronal 
markers, indicating possible distinct functions. This adds complexity to our understanding 
of their contribution to the spinal circuity of pain transmission and modulation.  
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Figure 3-8. Y1R is expressed by several subpopulations of excitatory 
interneurons in the dorsal horn   
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve rats were co-
labelled with antibody against Y1R, and antibodies against calbindin (Calb), calretinin 
(Calr), PKCγ or somatostatin (SST). Each image consists of a single confocal section 
taken with a 100x objective at the middle of the histological section from Lamina II. 
Dorsal side is up. Images in B, D, and F are zoomed in from the white square boxes shown 
in A, C, and E respectively. A, B) Y1R and calbindin immunoreactivities; C, D) Y1R and 
calretinin immunoreactivities; E, F) Y1R and PKCγ immunoreactivities; G) Y1R and 
somatostatin immunoreactivities. Arrowheads indicate instances of Y1R colabelling. 
Scale bars: 10 µm.  
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Figure 3-9. Quantification of the effect of SNI on co-labelling of Y1R with 
calbindin and calretinin in lamina II  
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve and SNI day 14 
rats were double labelled as indicated. Images were obtained from lamina II of dorsal 
horn. Two images were taken per side per section, one from the medial and the other 
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from the central-lateral aspect. Co-labelling was measured by calculating the 
percentage of double-labelled profiles relative to each of the single-labelled profiles. 
A) Quantification of co-labelling of Y1 and calbindin; B) Quantification of co-labelling of Y1 
and Calretinin. Three sections were analysed for each animal. n= 3. Values represent 
mean ± SEM. #p < 0.05 vs naïve group. Turkey post-hoc test is following one-way ANOVA. 
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Figure 3-10. Co-localization calbindin and calretinin in the dorsal horn 
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve rats were co-
labelled with antibodies against calbindin (Calb) and calretinin (Calr). The representative 
image consists of a single confocal section taken with a 63x objective in the middle of 
the histological section from Lamina II. Dorsal side is up. A) calbindin and calretinin 
immunoreactivities; B) quantification of calbindin and calretinin co-localization. 
Arrowheads indicate instances of co-localization. Scale bar: 10 µm. n= 3. Values represent 
mean ± SEM. Turkey post-hoc test is following one-way ANOVA. 
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3.3.6  Y1R co-labelling profile with calbindin and calretinin after nerve injury   
Next, I investigated whether nerve injury changes the Y1R co-labelling profile with 
calbindin and calretinin. L4-L6 lumbar spinal cord tissue from rats that were 14 days 
following SNI surgery was processed for the double-labelling study, and quantification was 
performed. As illustrated in Figure 3-9A, I found that nerve injury led to an increase of the 
percentage of Y1R cells that co-expressed calbindin from 35.73% to 58.58% in the medial 
aspect of the spinal cord ipsilateral side to nerve injury (F2,6 = 5.38, P = 0.046). In contrast, 
the percentage of Y1R cells that co-expressed calbindin in the central-lateral aspect of the 
ipsilateral side was not changed by nerve injury (P > 0.05). However, SNI decreased the 
percentage of calbindin cells that co-expressed Y1R in the central-lateral aspect of the 
ipsilateral side (F2,6 = 6.505, P = 0.0314). In addition, SNI lead to an overall decrease of 
the percentage of calbindin cells that co-expressed Y1R in both medial and central-lateral 
aspect of both ipsilateral and contralateral side (F2,6 = 5.73, P = 0.0406). 
As illustrated in Figure 3-9B, I observed no changes in the Y1 co-labelling profile with 
calretinin after nerve injury (P > 0.05). 
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3.4  Discussion 
3.4.1  Y1R is not expressed in glia in the spinal cord 
Y1R has been intensively studied in pain related research under the assumption that 
they are expressed only in neurons (Brumovsky et al. 2007).  Although glia have emerged 
as powerful modulators of pain and novel targets for its treatment (Milligan et al. 2009), 
whether NPY could elicit anti-hyperalgesic properties through Y1R by modulating glia 
activity is not well studied. An early study reported Y1R-LI in astrocytes of nucleus 
accumbens (Pickel et al. 1998). Several in vitro studies with cultured astrocytic (Hosli et 
al. 1992, Abounader et al. 1999, St-Pierre et al. 2000) or microglial (Ferreira et al. 2010, 
Ferreira et al. 2011, Goncalves et al. 2012) lineage cells observed Y1R mRNA or 
expression. These studies suggest that disease or stress might induce expression of Y1R 
in glia. If do, then NPY could potentially inhibit glial activation as a mechanism of pain 
inhibition. However, our new data do not support this hypothesis. Here we have shown, 
for the first time, that Y1R is exclusively located in neurons, but not in glia, in the superficial 
dorsal horn of the spinal cord. This remains true after cutaneous inflammation or 
peripheral nerve injury. Our data suggest that spinal Y1R solely engages neurons to 
modulate in pain circuity. However, this exclusivity must be corroborated with further 
studies using alternative species, and alternative methods to quantify expression including 
western blot (protein) and PCR (mRNA).  
 
3.4.2  Y1R in dorsal horn neurons and SP-containing primary afferents 
[Texts inside {} in this subsection have been extracted from the previously published 
(Taylor et al. 2014).] 
The presence of Y1R in primary afferent terminals in the superficial lamina of dorsal 
horn is controversial (Brumovsky et al. 2007). {Taylor, 2014, see {Taylor, 2014 `#255}]. 
However, despite the clear presence of Y1R immunoreactivity in DRG neurons, we 
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could not identify Y1R immunoreactive primary afferent axons or terminals in the dorsal 
horn, due to lack of co-localization with CGRP, SP or IB4. The same problem was 
reported by Brumovsky et al. (Brumovsky et al. 2002): they found Y1R immunoreactivity 
in CGRP-positive DRG cell bodies and fibers in the sciatic nerve and dorsal roots, but 
almost no Y1R and CGRP co-localization in fibers in the dorsal horn. Moreover, dorsal 
rhizotomy did not change Y1 R staining in the dorsal horn, but completely depleted 
CGRP staining. To explore this issue in depth, we obtained high magnification confocal 
images of laminae I–II from sections double- and triple-labelled for Y1R, CGRP, SP and 
IB4, and analyzed the co-localization of label pairs voxel-by-voxel in the whole confocal 
stacks. This state-of-the-art quantitative analysis failed to reveal any co-localization of 
Y1R with CGRP or SP, whereas the co-localization of CGRP with SP (used as a positive 
control) was high, as expected. One possible explanation is that Y1R is expressed in 
DRG neurons but not transported centrally into the spinal cord. However, this is unlikely 
because Brumovsky et al., (Brumovsky et al. 2002) found Y1R immunoreactivity in the 
dorsal roots. A second possibility is that Y1R binds to proteins in primary afferent 
terminals that hinder the binding of the antibody used to label it, as happens with 
NMDAR (Nagy et al. 2004). A third possibility, which we favor, is that the lack of co-
localization is an artifact caused by the masking of Y1R in primary afferent axons by the 
stronger immunoreactivity signal of Y1R in dorsal horn neurons (Ji et al., 1994). Indeed, 
while DRG and spinal cord sections were stained using the same antibody 
concentrations, a higher photomultiplier gain of the confocal microscope was used to 
acquire images from the DRG (880–985) than from the dorsal horn (540–800), indicating 
that Y1R is denser in dorsal horn neurons. This, together with the thinness of the primary 
afferent axons, may have hindered the identification of Y1R in them. 
Our immunohistochemical studies are consistent with previous studies describing Y1R 
in DRG neurons that contain calcitonin gene-related peptide (CGRP) and in small dorsal 
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horn neurons in laminae I–III (Ji et al. 1994, Zhang et al. 1994, Brumovsky et al. 2002). 
Some of the Y1R neurons in lamina I project to the brain, and most seem to be excitatory 
neurons under the inhibitory influence of NPY and Y1R (Brumovsky et al. 2006, Polgar et 
al. 2013). We found that the volume of primary afferent axons in the dorsal horn is very 
small compared with the volume of Y1R-expressing dorsal horn neurons and their 
dendritic processes. Furthermore, the density of Y1R in primary afferents was small 
compared with their density in dorsal horn neurons - so small indeed that they could not 
be detected with immunohistochemistry. Therefore, the majority of Y1R in the dorsal horn 
are most likely located in dorsal horn neurons. However, even scant Y1R on afferent 
terminals, if avidly coupled, could account for a significant or even large proportion of 
overall NPY signaling in dorsal horn.} 
 
3.4.3  Y1R-expressing neurons are excitatory interneurons that may be heavily engaged 
in pain transmission 
Based on a synthesis of behavioral and electrophysiological data available at the time, 
our earlier models of NPY analgesia included a mechanism involving disinhibition of 
inhibitory neurotransmitter release (Smith et al. 2007). However, this hypothesis requires 
that a proportion of Y1R neurons are inhibitory: this was not supported by unpublished 
data from our lab collected by Greg Corder and Renee Donahue using a spinal NPY-
saporin delivery strategy to ablate Y1R-expressing neurons in the dorsal horn. Their data 
suggested that ablation of Y1R-expressing neurons delayed the onset and reduced the 
intensity of the non-noxious mechanical, noxious mechanical, and cold hypersensitivities 
associated with peripheral nerve injury, an effect that lasted many weeks. These data 
suggested that Y1R-expressing neurons are excitatory, and heavily engaged in pain 
processing and facilitation after nerve injury. 
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 My findings in this chapter supports this conclusion. Y1R-expressing neurons are 
mostly positive for an excitatory interneuron marker Tlx3, and negative for a marker of 
inhibitory interneurons, Pax2. In addition, I found that Y1R co-exist with multiple markers 
of excitatory neurons such as somatostatin, calbindin, and calretinin, indicating that Y1R-
expressing neurons in lamina II exert a strong facilitatory influence on pain. Thus, 
regarding the mechanism by which endogenous NPY tonically inhibits peripheral 
neuropathic pain, we conclude this is more likely by silencing Y1R-expressing excitatory 
interneurons, rather than through disinhibition of Y1R-expressing inhibitory interneurons.  
I found that most Y1R-immunoreactive neurons in lamina II contain somatostatin-like 
immunoreactivity, as described before (Zhang et al. 1999). Selective ablation of 
somatostatin lineage neurons, using an intersectional genetic strategy, decreased 
mechanical allodynia associated with SNI in the mouse. These data suggest that spinal 
somatostatin-positive excitatory interneurons transmit the mechanical modality of 
neuropathic pain (Duan et al. 2014). This is consistent with Corder and Donahue data that 
a large population of Y1R-expressing neurons is responsible for transmission of 
mechanical hypersensitivity after nerve injury. 
Calbindin and calretinin are primarily located in different sub-populations of dorsal horn 
neurons (Ren et al. 1994) and are largely (but not exclusively) restricted to glutamatergic 
cells (Todd 2010, Smith et al. 2015). For the first time, I show that both are contained in 
Y1R-immunoreactive neurons. While little is known about the function of calbindin-positive 
neurons, a recent pair of high profile studies suggest a differential contribution of two 
populations of calretinin neurons to somatosensation. One population permanently 
expresses calretinin but not Lbx1 [a transcription factor that distinguishes two major fates 
of somatosensory interneurons in the dorsal horn of spinal cord (Gross et al. 2002, Muller 
et al. 2002)] and is involved in mechanical hypersensitivity, as suggested by the 
observation that selective pharmacogenomic activation of adult calretinin neurons 
104 
 
 
produced behavioral signs of mechanical hypersensitivity and non-noxious stimulus-
evoked Fos expression in calretinin+ neurons (Peirs et al. 2015). A second population 
transiently expresses calretinin with Lbx1 during development and is involved in light 
punctate sensation but not mechanical hypersensitivity, as suggested by the observation 
that selective ablation of Lbx1+ calretinin lineage neurons increased von Frey threshold 
but not the mechanical allodynia associated with SNI (Duan et al. 2014). However, 
because the above studies either did not activate adult calretinin neurons in a neuropathic 
pain model (Peirs et al. 2015) or did not ablate adult calretinin neurons (Duan et al. 2014), 
further studies will be required to determine whether and which calretinin+ subpopulation 
of Y1R neurons contribute to neuropathic pain. 
PKCγ-immunoreactive neurons are present throughout laminae I–III (Malmberg et al. 
1997, Polgar et al. 1999), particularly in the ventral half of lamina II where their dendrites 
form a dense plexus (Hughes et al. 2003). Although PKCγ-immunoreactive cell bodies 
make numerous contacts with NPY-positive boutons and dendrites (Polgar et al. 2011) 
and thus might appear to be a candidate for co-expression with Y1R, this population is 
largely distinct from the calbindin and calretinin populations, and did not co-label with Y1R 
in the current studies. We conclude that the vast majority of Y1R-expressing cells are 
excitatory interneurons that lie dorsal to the ventral inner lamina II band that is demarcated 
by PKCγ staining. 
 
3.4.4  Nerve injury induces plasticity of Y1R expression in excitatory and inhibitory 
interneurons 
Here I have shown for the first time that nerve injury changes the Y1R expression 
profile in interneurons. At the peak of SNI-induced mechanical hypersensitivity (day 14 
post surgery), I found that, ipsilateral to spared nerve (sural) transection, Y1R expression 
was decreased in the Tlx3-positive excitatory interneurons, while increased in the Pax2-
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positive inhibitory interneurons in the sural innervation territory of Lamina II. A shift of Y1R 
expression from excitatory to inhibitory interneurons could be part of the spinal central 
sensitization mechanism, replacing NPY inhibition with disinhibition, and thus contributing 
to the development of hypersensitivity following nerve injury. Please refer to Chapter 5, 
section 5.1.2 for schematic cartoons and further discussion about the shift of Y1R 
expression. We speculate that the shift of Y1R expression is unlikely due to changing the 
function of interneuron themselves, because both Tlx-3 and Pax-2 are transcriptional 
factors that determine the neuronal fate during embryonic development.  
 
3.4.5  What type of inhibitory interneuron gates the Y1R-expressing excitatory neuron? 
The classic Gate Control Theory of pain postulated that the input generated by 
nociceptive as well as non-nociceptive afferents is regulated by a complex, gated circuit 
in the dorsal horn. One of the central tenets of Gate Control Theory is that an inhibitory 
interneuron in the substantia gelatinosa responds to non-nociceptive input by inhibiting, 
or closing the gate on, a neuron that transmits pain messages to the brain (Melzack et al. 
1965). Recent studies indicate that gating might also occur at excitatory interneurons, 
including those that express somatostatin, VGLUT3, or PKCγ (Duan et al. 2014, Peirs et 
al. 2015, Petitjean et al. 2015). Based on a large body of anatomical, behavioral, and 
electrophysiological evidence, we speculate that the Y1R-expressing excitatory 
interneurons described here would be gated by an inhibitory NPY-expressing interneurons 
that release NPY (Smith et al. 2007). First, extensive anatomical evidence describes a 
large subset of GABA-expressing interneurons that co-express NPY. Second, we reported 
that endogenous NPY tonically inhibits neuropathic pain behavior (Solway et al. 2011). 
Third, Smith and colleagues described inhibitory actions of NPY on the neurophysiological 
activity of dorsal horn neurons (Moran et al. 2004). 
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Functional studies are required to test the hypothesis that NPY-expressing 
interneurons gate the activity of Y1R-expressing interneurons that drives neuropathic pain. 
Such studies are emerging. For example, intersectional genetic ablation of NPY lineage x 
Lbx1 lineage neurons, the latter of which is expressed in dorsal horn neurons, did not 
change hypersensitivity in the CFA model of acute inflammatory pain (Bourane et al. 
2015). But we think these results do not preclude gating of chronic neuropathic pain by 
NPY-expressing interneurons for two reasons. First, this approach ablated both transiently 
and permanently NPY-expressing interneurons, which are different from the population of 
neurons that only permanently express NPY. Second, this model was only tested at one 
early time point in one model of inflammation (intraplantar CFA) induced hypersensitivity; 
the contribution of NPY interneurons could be quite different at later timepoint after 
inflammation, timepoints that are more reflective of chronic pain.   
Indeed, as discussed in Chapter 2, a previous publication from our lab reported that 
conditional NPY knockdown leads to exacerbation of pain-like behaviors in both 
inflammatory and neuropathic pain models; this was likely mediated by spinal Y1R 
because an intrathecal injection of an Y1R antagonist in the latent sensitized state 
reinstated these pain-like behaviors (Solway et al. 2011). In addition, a recent study using 
NPY-GFP mice suggested that NPY-positive inhibitory interneurons are innervated by a 
subset of C-fibers, and can be activated by peripheral noxious mechanical stimuli (Iwagaki 
et al. 2016). Thus, we consider the spinal NPY-expressing inhibitory interneurons as a 
promising candidate to serve as the “gate”.  
Recent studies point to inhibitory, parvalbumin-expressing dorsal horn neurons as 
gate-keepers of neuropathic pain (Petitjean et al. 2015), and one might wonder whether 
these neurons provide the synaptic NPY that gates Y1R-expressing interneurons.  We 
think this is unlikely for two reasons. First, the NPY and parvalbumin (and galanin and 
neuronal nitric oxide synthase) subpopulations of inhibitory GABA-expressing neurons are 
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thought to be segregated and non-overlapping (Laing et al. 1994, Braz et al. 2014). 
Second, my current data indicate that Y1R-expressing neurons are distinct from PKCγ-
expressing neurons, the subpopulation of excitatory interneurons thought to be the 
primary gating target of pain inhibitory parvalbumin interneurons (Petitjean et al. 2015). 
 
3.4.6  Summary and future studies 
1) Here I have shown for the first time that nerve injury produced plastic changes of 
the Y1R expression profile on interneurons. At the peak of SNI induced mechanical 
hypersensitivity (day 14 post surgery), I found that ipsilateral to the nerve injury, 
Y1R expression was decreased in the Tlx3-positive excitatory interneurons, while 
increased in the Pax2-positive inhibitory interneurons in the spared nerve 
innervation territory of Lamina II. A shift of Y1R expression from excitatory to 
inhibitory interneurons could be part of the spinal central sensitization mechanism, 
contributing to the development of hypersensitivity following nerve injury. Similar 
studies can be performed in CFA animals to study the inflammation produced 
plastic changes of the Y1R expression profile in interneurons. 
2) Although suggested to be excitatory, Y1R-expressing spinal interneurons are 
heterogeneous neurochemically and electrophysiologically. Unpublished data 
from our lab collected by Ghanshyam Sinha suggests that they consist of several 
subpopulations of interneurons with distinct neuronal markers and firing patterns. 
To understand their functions within each subpopulation in pain transmission and 
modulation, an intersectional genetic strategy (Duan et al. 2014) that restricts the 
excitatory or inhibitory DREADD receptor expression to the cells that co-labels 
Y1R and a specific interneuron marker (e.g. calbindin) can be used. Upon delivery 
of the DREADD ligand, clozapine N-oxide (CNO), these DREADD-engineered 
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cells will be excited or silenced. Behavioral studies can be performed in different 
animal models of pain. If i.t. CNO produces a pain-like response change after 
injury, it suggests the involvement of this specific subpopulation of Y1R+ 
interneurons in pain modulation. Electrophysiological studies can also be 
performed to reveal the role of these Y1R+ neurons in the Gate Control Theory of 
pain.  
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CHAPTER 4:  Peripheral nerve injury increases stimulation-induced neuropeptide 
Y release as measured by Y1 receptor internalization in the rat dorsal horn. 
 
4.1  Introduction  
It has been widely accepted that peripheral nerve injury greatly upregulates 
neuropeptide Y (NPY) in the dorsal horn of the spinal cord, as well as in DRG (Wakisaka 
et al. 1992, Ma et al. 1998, Ossipov et al. 2002, Intondi et al. 2010, Wang et al. 2012). In 
all of these studies, NPY level was either measured by NPY-like immunoreactivity (NPY-
LI), or by in situ hybridization or qPCR. The actual release of NPY from the spinal cord 
has been difficult to detect because of the lack of a sensitive and reliable assay. Our 
attempts to measure NPY in spinal microdialysate have failed despite our success with 
substance P dialysis (Kondo et al. 2005, Taylor et al. 2014). Previous publications from 
our lab suggest that tissue injury tonically increases NPY expression, NPY Y1 receptor 
(Y1R) signaling, and spinal anti-hyperalgesia (Intondi et al. 2010, Solway et al. 2011, 
Taylor et al. 2014), but whether this is due to tonic ligand-dependent Y1R activation has 
been difficult to study in the absence of a reliable assay of NPY release.  
Ligand-induced internalization of G-protein coupled receptors (GPCRs) has been well 
characterized in the literature (Sorkin et al. 2009). Measuring neurokinin 1 receptor 
(NK1R) and µ-opioid receptor (MOR) internalization as a functional assay to measure the 
release of substance P and opioids (Sternini et al. 1996, Trafton et al. 2000, Song et al. 
2003, Song et al. 2003, Chen et al. 2007, Chen et al. 2008, Chen et al. 2008, Chen et al. 
2009) has been extensively used (Mantyh et al. 1995, Sternini et al. 1996, Abbadie et al. 
1997, Song et al. 2003, Kondo et al. 2005). Y1R is a GPCR that exhibits a rapid and clear 
internalization from cell membrane to endosomes upon ligand binding (Kondo et al. 2005). 
Therefore, similar to the NK1R and MOR internalization assay, here we developed Y1R 
internalization as a new in situ assay of spinal NPY release. 
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4.2  Materials & Methods 
4.2.1  Animals 
     Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 
200-250 g at the time of surgery were used in the study. They were housed 1-2 per cage. 
All animals were housed in a lighting (12-h light/dark cycle for rats and 14-h light/dark 
cycle for mice), temperature (68-72º F) and humidity controlled room with food and water 
provided ad libitum. Animals were allowed a minimum of one week to habituate to the 
facility prior to their entrance into the study. All animal procedures were approved by the 
Institutional Animal Care and Use Committee of the University of Kentucky, followed the 
guidelines for the treatment of animals of the International Association for the Study of 
Pain, and conducted in full compliance with the Association for Assessment and 
Accreditation of Laboratory Animal Care. 
 
4.2.2  Spared Nerve Injury (SNI) model for neuropathic pain 
Please refer to section 2.2.3.2. Absorbable 5-0 sutures (Ethicon) were used to suture 
the muscle in rats. 
 
4.2.3  Behavioral testing for mechanical threshold  
       Please refer to section 3.2.3. 
 
4.2.4  Paw stimulation  
 At day 14 after SNI, rats were anesthetized with isoflurane (5% for induction and 3% 
for maintenance) and received a non-noxious (gentle stroke with the thumb of the 
experimenter for 2 sec, repeated every 4 sec for 2 min) or noxious stimulus (application 
of a 2-cm wide binder clip for 2 min) at the sural receptive field of the plantar skin ipsilateral 
to SNI. After paw stimulation, rats were left under isoflurane for another 5 minutes and 
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then perfused. Animals in the unstimulated group were anesthetized for the same amount 
of time as the stimulated aniamls, but without paw stimulation.  
 
4.2.5  Immunohistochemistry 
 Rats were deeply anesthetized with isoflurane, and perfused with 200ml 0.1 M PBS 
containing heparin (10,000 USP units/L) followed by 200 ml 10% phosphate buffered 
formalin (Fisher Scientific, Pittsburgh, PA).  Lumbar spinal cords were dissected and post-
fixed in 10% formalin for 4h, cryoprotected in 30% sucrose overnight, and sectioned 
transversely at 50 μm (L4-L6) on a freezing microtome for. The sections were washed 3 
times in 0.1 M PBS and then pretreated with blocking solution [3% normal goat serum 
(Gemini Bio Products, Broderick, CA) and 0.3% Triton X-100 (Sigma-Aldrich, St Louis, 
MO) in 0.1 M PBS] for 1 hour. Sections were incubated overnight at room temperature in 
antibody dilution solution (1% normal goat serum and 0.3% Triton X-100 in 0.1 M PBS) 
with rabbit anti-Y1 (1: 1,000, Janice Urban). Sections were then washed, incubated in 
antibody dilution solution with the secondary antibody Alexa 568-conjugated goat anti-
rabbit (1:1000, Invitrogen, Carlsbad, CA) for 1.5h at room temperature, washed again, 
mounted onto Superfrost Plus slides, air dried, and coverslipped using Prolong Gold with 
DAPI mounting medium (Molecular Probes, Eugene, OR).  
 
4.2.6  Confocal microscopy and image processing  
       Please refer to the 3rd paragraph of section 3.2.7. An 63x oil immersion objective 
(numerical aperture 1.4) was used. 
 
4.2.7  Quantification of Y1R internalization 
We adapted our assay of Y1R internalization from the established NK1R and MOR 
internalization assays that were developed to measure the release of substance P 
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(Mantyh et al. 1995, Abbadie et al. 1997, Kondo et al. 2005) and opioids (Sternini et al. 
1996, Trafton et al. 2000, Song et al. 2003, Chen et al. 2009) respectively. Y1R-
immunoreactive neurons were considered to have internalized receptors when ≥ 5 
endosomes were observed inside the soma and could be clearly seen to be dissociated 
from the cell membrane. The experimenter, Weisi Fu, was self-blinded to treatment 
groups as well as ipsi-/contralateral sides during the quantification. 
 
4.2.8  Statistical Analysis  
Data were analyzed using Prism software (GraphPad, San Diego CA), two-way analysis 
of variance (ANOVA) followed with Bonferroni’s post-hoc tests. All data are expressed as 
mean ± SEM. Statistical significance was set at P < 0.05.  
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4.3  Results 
4.3.1  SNI increases NPY release induced by sensory stimulation of the hindpaw  
We developed Y1R internalization as a new in situ assay of spinal NPY release in 
collaboration with Dr. Juan Carlos Marvizon. In collaboration with our own group, he found 
that in spinal cord slices, exogenous NPY dose dependently induced Y1R internalization. 
In addition, electrical stimulation of the dorsal roots induced Y1R internalization. Moreover, 
Y1R internalization induced by dorsal horn stimulation was increased 14 days after SNI 
(unpublished data, not shown). 
To extend this assay, I evaluated Y1R internalization in rats in situ, by substituting 
electrical stimulation of the dorsal horn with non-noxious or noxious mechanical 
stimulation of the sural receptive field of the plantar skin ipsilateral to SNI in anethetized 
rats at 14 days after SNI. Figure 4-1 provides examples of internalized Y1R neurons 
(Figure 4-1A, B) and non-internalized neurons (Figure 4-1C, D). I found that both non-
noxious (p < 0.0001) and noxious stimulation (p < 0.0001) markedly increased Y1R 
internalization in the dorsal horn ipsilateral but not contralateral (p > 0.05) to SNI (Figure 
4-1E, interaction: F2,32 = 6.81, p = 0.0033; side: F1,32 = 39.97, p < 0.0001; stimulation: F2,32 
= 16.64, p < 0.0001). We conclude that after nerve injury, sensory stimulation evokes NPY 
release from peripheral nociceptors or from neurons receiving synapses from them. A 
future study with a sham control group needs to be performed to support the conclusion 
that SNI increases NPY release induced by sensory stimulation of the hindpaw. 
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Figure 4-1. After nerve injury, mechanical stimulation of the hindpaw increases 
NPY release (Y1R internalization) in the ipsilateral dorsal horn 
Transverse sections of lumbar spinal cord (L4–L6) taken from SNI day 14 rats were 
co-labelled with antibody against Y1R. The representative images consist of a single 
confocal section taken with a 63x objective at the middle of the histological section 
from Lamina II. Dorsal side is up. A, B) examples of Y1R neurons with Y1R internalization; 
C, D) examples of Y1R neurons without Y1R internalization. E) quantification of 
percentage of Y1R neurons with internalization. Scale bar: 10 µm. n= 5-7. Values 
represent mean ± SEM. ★p < 0.05 vs contralateral side; #p < 0.05 vs no stimulation 
ipsilateral side. Bonferroni’s post-hoc test is following two-way ANOVA. 
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4.4  Discussion 
4.4.1  Significance 
Here, we have successfully developed a novel in situ assay of spinal NPY release by 
measuring Y1R internalization. Receptor internalization has several advantages over 
other methods to measure neuropeptide release such as microdialysis, antibody 
microprobes and peptide immunoassays: 1) it allows the localization of the areas of 
release (segment, side, lamina, etc.); 2) it is an in situ measure and thus avoids problems 
with extracting the peptide; 3) it is sensitive; 4) it is non-invasive; 5) it detects peptide 
release that is physiologically relevant in terms of receptor activation.  
  
4.4.2  The increase of spinal NPY release is peripheral input-dependent in SNI animals 
My data suggest that the increase of spinal NPY release ipsilateral to the nerve injury 
is sensory input-dependent, because the non-stimulated animals did not exhibit increased 
Y1R internalization ipsilateral to the nerve injury. However, a previous publication from our 
lab detected an increase of NPY-LI in the central-lateral region (innervated by the sural 
nerve) of the ipsilateral side 2 weeks after SNI, with that in the medial region (innervated 
by the tibial nerve) unaffected, without periphery sensory stimulation (Intondi et al. 2010). 
Taken together, these data suggest that, 2 weeks after SNI, NPY synthesis in the spared 
nerve innervation territory is increased. However, NPY is only released from NPY-
containing cells in case of peripheral input. Future studies are needed to further address 
this question. Once an uninjured animal control group is added, we will able to determine 
in situ 1) if SNI produces increased tonic NPY release without sensory stimulation on both 
sides of the spinal cord, and 2) if the sensory stimulation-induced spinal NPY release is 
greater in the ipsilateral side from nerve injured animals as compared with sham controls.  
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4.4.3  Sustained NPY release may not decrease Y1R level in the spinal cord  
An in vitro study with human NPY Y1R transfected in HEK cells suggested that after 
rapid internalization, the Y1R was targeted to clathrin-coated pits, instead of lysosomes, 
suggesting a recycling instead of degradation pathway (Gicquiaux et al. 2002). This is 
consistent with the literature (Brumovsky et al. 2004) and our previous finding (Figure 3-
7) showing that peripheral nerve injury does not decrease the number of Y1R -expressing 
neurons in the spinal cord. We conclude that any natural stimulus-evoked NPY release 
does not lead to a compensatory down-regulation of Y1R.   
 
4.4.4  Source of NPY released after SNI: primary afferent terminals or spinal 
interneurons? 
There are three possible sources for the increased spinal NPY release that we 
detected upon peripheral stimulation after SNI: From primary afferent terminals, from 
neurons receiving synapses from primary afferent terminals, or from descending excitatory 
supraspinal neurons following processing of afferent information in the brain. Normally 
NPY is not detectable in DRG neurons (Gibson et al. 1984, Zhang et al. 1993, Corness et 
al. 1996). However, nerve injury can cause a dramatic increase of NPY transcripts and 
expression in medium to large diameter DRG neurons (Wakisaka et al. 1991). Upon 
activation of these primary afferent fibers (mostly A fibers), NPY could be released to the 
spinal cord (Mark et al. 1998). This could be the main source of NPY release we saw after 
non-noxious light touch stimulation (Figure 4-1). In addition, there is a population of NPY-
expressing GABAegergic inhibitory internal neurons in Laminae I-III (Polgar et al. 2011). 
These neurons receive inputs from C-fibers and can be activated by noxious stimuli 
(Polgar et al. 2013, Iwagaki et al. 2016). These NPY-expressing inhibitory interneurons 
could be the major source of NPY release we saw after noxious pinch (Figure 4-1). 
4.4.5  Future studies 
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1) Several studies are needed to further validate this novel functional assay.  
1.1 ) In situ study with SNI and Sham control groups to test the hypothesis that a) 
SNI produces tonic NPY release without sensory stimulation on both sides of 
the spinal cord; b) Sensory stimulation-induced spinal NPY release is greater 
at the ipsilateral side day 14 days after SNI as compared with sham animals. 
1.2 ) As stated above, NPY could be released directly from central terminals of 
primary afferents or indirectly from NPY-containing inhibitory interneurons 
receiving synapses from those terminals. To determine the source of the 
release, we could conduct paired-pulse studies using patch clamp spinal cord 
slice electrophysiology, with dorsal root stimulation. These 2 possibilities can 
be distinguished by inhibiting 1st order synapses with AMPAR antagonist 
CNQX (5 µM) (Marvizon et al. 1997) during stimulation. If CNQX produce no 
effect, it suggests that NPY is released from primary afferents. 
1.3 ) Immunohistochemistry study to co-label Y1R and clathrin is needed to confirm 
that the dot-like Y1R staining, presumably vesicular endosomes, reflect 
clathrin-coated vesicles for internalization. Clathrin antibodies are 
commercially available. 
2) We previously found that the suppression of hyperalgesia during the remission 
phase of inflammation- or nerve injury-induced LS is mediated by at least in part 
by Y1R and Y2R (Solway et al. 2011). We now hypothesize that this is caused by 
sustained increase of NPY release in the dorsal horn after injury. We now can use 
the Y1R internalization assay to measure NPY release in inflammation (CFA) and 
nerve injury models (CpxSx). More specifically, we predict that dorsal root 
stimulation in slices or paw stimulation in vivo will upregulate Y1R internalization 
during the pain remission phase of either the CpxSx and CFA models. Although it 
is controversial in literature whether the NPY level in the dorsal horn is upregulated 
118 
 
 
after inflammation (Wakisaka et al. 1992, Ji et al. 1994), we predict that peripheral 
stimulation induced NPY release is increased, because long-lasting suppression 
of hyperalgesia after injury by the NPY system is a ligand-dependent event (refer 
to section 2.4.1). The source of released NPY is likely the NPY-containing 
inhibitory interneurons, because NPY is not present in DRG after inflammation.  
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CHAPTER 5:  Conclusion and Final Discussion  
5.1  Conclusion 
5.1.1  Injury induces a pronociceptive signaling pathway that is inhibited by the 
endogenous NPY-Y1 axis 
We developed a novel functional in situ assay of NPY release by measuring Y1R 
internalization in the spinal cord. Using this assay, my data indicate that nerve injury 
increases spinal NPY release induced by sensory stimulation of the hindpaw. We 
speculate that injury causes a sustained facilitation of endogenous NPY release and Y1R 
activation in the spinal cord, thereby silencing the LS. We characterized a branched 
signaling pathway (Figure 5-1) which drives LS during pain remission, NMDAR  AC1  
PKA TRPA1/V1 and NMDAR  AC1  Epac1/2. We have demonstrated that this 
pathway is under the tonic inhibition of endogenous NPY-Y1R axis, thus keeping pain in 
remission. 
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Figure 5-1. Working model for the intracellular signaling pathways by which the 
endogenous NPY-Y1 axis inhibits LS and possibly chronic pain. 
Line Arrows denote activation/production; Line Dots denote inhibition; Black, 
processes or drugs; Red, candidates studied in Chapter 2; Gray, candidates not 
directly studied in Chapter 2. Abbreviations can be found in the Appendix. 
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5.1.2  Spinal Y1R-expressing cells in the context of Gate Control Theory 
In this dissertation, we have demonstrated that Y1R is exclusively expressed in 
neurons but never glia in Lamina II of superficial dorsal horn of the spinal cord. 
Furthermore, we characterized Y1R-expressing cells by co-labelling Y1R with multiple 
excitatory and inhibitory neuronal markers. We found that Y1R is almost exclusively 
expressed in excitatory and rarely in inhibitory interneurons. In addition, Y1R-expressing 
cells are heterogeneous, with subpopulations that co-express somatostatin, calbindin, and 
calretinin, respectively. Y1R and PKCγ labels distinct population of excitatory 
interneurons. To understand the plasticity of Y1R-expressing cells after injury, we then 
quantified the co-labelling profile after spared nerve injury. We found that nerve injury 
decreases the co-labelling of Y1R with excitatory interneurons and correspondingly 
increases that with inhibitory interneurons in the spared nerve innervation territory of the 
ipsilateral side of the spinal cord.  
Figure 5-2 illustrates our speculated contributions of NPY- and Y1R- neurons within 
the context of the Gate Control Theory: NPY- expressing interneurons could be “IN” cells 
to gate, while Y1R-expressing interneurons could be “E” cells to relay pain transmission. 
This is based on the on the literature and our current findings suggesting as follows: 
1) Recent publications have identified roles of somatostatin- and calretinin-
interneurons in the wiring of the Gate Control Theory. Lamina II somatostatin+ neurons 
receive direct inputs from Aδ and Aβ-fibers, contributing to mechanical hypersensitivity 
transmission associated with spared nerve injury (Duan et al. 2014). Calretinin-expressing 
neurons in lamina II are the bridge connecting VGLUT3 cells in lamina III, which receive 
input from Aβ-fibers, and NK1+ projection neurons in Lamina I that send mechanical pain 
information to the brain (Peirs et al. 2015). 
2) NPY-expressing inhibitory interneurons are demonstrated to: a) receive input from 
TRPV1+ (Polgar et al. 2013) and/or TPRV1- (Iwagaki et al. 2016) nociceptors; b) form 
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synaptic contacts with NK1+ projection neurons in Lamina III (Polgar et al. 1999); and c) 
receive inputs from Aβ fibers (Bourane et al. 2015).  Therefore, we conclude that Y1R is 
expressed on these somatostatin and calretinin positive excitatory interneurons which are 
engaged in relaying pain transmission. We propose that endogenous spinal NPY exerts 
inhibitory control either as synaptic inhibitor (NPY+ inhibitory interneurons synapse on 
somatostatin and calretinin positive interneurons that are also Y1R+ and release NPY on 
these interneurons), or as an extra-synaptic inhibitor (NPY+ inhibitory interneurons 
release NPY which diffuse to the Y1+ pain transmitting interneurons), decreasing the 
excitability of the Y1R-expressing cells.  
We found that nerve injury induces plasticity in the Y1R-expressing pattern, leading to 
a shift of Y1R expression from excitatory to inhibitory interneurons at the peak of 
hyperalgesia. We speculate that this is a maladaptive change of the wiring system that 
contributes to neuropathic pain. As illustrated in Figure 5-2B, a possible scenario is that 
two weeks after SNI, Y1R is expressed in some of the inhibitory interneurons that synapse 
on pain relaying excitatory interneurons or projection neurons. We hypothesis that NPY 
disinhibits the pain circuit, thus countering the ability of the endogenous NPY/Y1R axis to 
exert an overall inhibitory influence on chronic pain.  
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Figure 5-2. Proposed contribution of Y1R neurons in the dorsal horn 
microcircuitry of pain before and after nerve injury. 
A) Before injury; B) Two weeks after nerve injury. Line Arrows denote activation; 
Line Dots denote inhibition; Double Line Arrows denote polysynaptic connection; 
Line Dots with question mark denote speculated connection which has not been 
demonstrated in literature. NK1, projection neurons in Lamina I and III; SST, 
somatostatin-positive excitatory interneurons; Calr, calretinin-positive excitatory 
interneurons. Other abbreviations can be found in the Appendix. 
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5.2  General discussion 
5.2.1  Does the endogenous NPY system works in concert with other endogenous pain 
inhibitory systems to silence LS? 
Besides the endogenous NPY system discussed throughout this dissertation, it must 
be recognized that other pain modulatory systems in the spinal cord may also exert 
endogenous analgesic function to mask LS; these include the opioid and 
endocannabinoid systems. A previous publication from our lab reported that blockade of 
constitutive µ-opioid receptor activity leads to withdrawal behaviors including pain 
reinstatement (Corder et al. 2013). In addition, an unpublished study from our lab, 
conducted by Lilian Custodio-Patsey and Renee Donahue, suggests that spinal 
administration of cannabinoid receptor antagonists elicit pain reinstatement during 
remission. Furthermore, dual antagonism of CB1 and CB2 receptors prevents the 
resolution of postoperative pain (Alkaitis et al. 2010). These data suggest that 
multiple endogenous modulatory systems must work in concert to prevent the 
transition from acute to chronic pain, in such a way that, in case one systems fails, 
the pain will not be silenced by the other systems. This scenario adds complexity to 
the whole picture. Further studies to address the interaction between the different 
inhibitory systems could be beneficial for therapeutic strategy innovation, and these 
studies are ongoing in the Taylor laboratory. 
 
5.2.2  Possible new drug targets for pain management 
To conclude, our long-term goal to manage chronic pain is to: 1) increase 
endogenous NPY analgesia, thus keeping LS in remission; or 2) extinguish LS 
altogether. Based on our finding, the LS that is masked by both endogenous NPY and 
opioid systems shares the pronociceptive NMDAR-AC1 signaling pathway. Future 
studies need to be performed to determine if the pathway that drives LS downstream of 
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AC1 are also in common. This points to AC1 as a promising target to extinguish LS, as 
pain reinstatement is absent in AC1KO mice during inhibition of NPY or opioid systems. 
Gene modification or pharmacological block with AC1 specific blockers is an important 
future direction to take for analgesic drug development, and indeed clinical trials are being 
conducted by Min Zhuo (University of Toronto, personal communication). 
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CHAPTER 6:  Supplemental chapter--Activation of cannabinoid CB2 receptors 
reduces hyperalgesia in an experimental autoimmune encephalomyelitis 
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6.1  Abstract 
 Clinical trials investigating the analgesic efficacy of cannabinoids in multiple sclerosis 
have yielded mixed results, possibly due to psychotropic side effects mediated by 
cannabinoid CB1 receptors. We hypothesized that a CB2-specific agonist (JWH-133) 
would decrease hyperalgesia in an experimental autoimmune encephalomyelitis mouse 
model of multiple sclerosis. 4 weeks after induction of experimental autoimmune 
encephalomyelitis, we found that intrathecal administration of JWH-133 (10-100 µg) dose-
dependently reduced both mechanical and cold hypersensitivity without producing signs 
of sedation or ataxia. The anti-hyperalgesic effects of JWH-133 could be dose-
dependently prevented by intrathecal co-administration of the CB2 antagonist, AM-630 (1-
3 µg). Our results suggest that JWH-133 acts at CB2 receptors, most likely within the 
dorsal horn of the spinal cord, to suppress the hypersensitivity associated with 
experimental autoimmune encephalomyelitis. These are the first pre-clinical studies to 
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directly promote CB2 as a promising target for the treatment of central pain in an animal 
model of multiple sclerosis. 
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6.2  Introduction 
Multiple sclerosis (MS) is an autoimmune-inflammatory neurodegenerative disease of 
the central nervous system that afflicts well over 2 million people worldwide. MS disrupts 
the function of the brain, spinal cord and optic nerves and is characterized by acute 
inflammation, demyelination and axonal and neuronal loss.  Neuropathic pain is one of the 
most frequent symptoms of MS, reported by roughly half of all patients (Foley et al. 2013). 
MS patients present not only with spontaneous pain, but also several forms of evoked pain 
including cutaneous mechanical and cold hypersensitivity in the distal extremities 
(Osterberg et al. 2005, Truini et al. 2013). Despite its heavy impact on patient quality of 
life, pain in MS is often neglected or undertreated. Conventional analgesics either show 
low efficacy or produce unwanted side effects (Nick et al. 2012). 
Emerging data suggest that activation of endogenous cannabinoid receptors can 
suppress neuropathic pain (Rahn et al. 2009, Landry et al. 2012). Cannabinoid receptor 
(CB) subtypes include CB1 and CB2. CB1 is predominately located in neurons within the 
central nervous system, while CB2 is localized primarily on immune and microglial cells 
(Munro et al. 1993). CB2-immunoreactivity is significantly up-regulated at the lesion sites 
of post-mortem human spinal cord from patients with MS (Yiangou et al. 2006), as well as 
4 weeks after MOG33-55-induction of EAE in mice (Palazuelos et al. 2008, Lou et al. 
2011). 
Double-blind randomized controlled trials on the analgesic efficacy of the CB1/CB2 
agonist Sativex, an oromucosal spray of tetrahydrocannabinol and cannabidiol, have 
yielded mixed results (Wade et al. 2004, Iannitti et al. 2014).  Other CB agonist 
preparations such as delta-9-tetrahydrocannabinol or nabilone consistently reduce MS 
pain, but at the expense of dizziness, headache, fatigue and/or impaired judgment 
(Svendsen et al. 2004, Wissel et al. 2006, Zajicek et al. 2012). Mixed results are likely due 
in part to the psychotropic side effects associated with CB1 activation, and point to the 
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CB2 as an attractive target for chronic pain (Malan et al. 2003, Anand et al. 2009). To 
date, however, an exhaustive literature search indicates that no study has evaluated the 
efficacy of a CB2 selective agonist for pain in MS. Here we address this question in a 
validated experimental autoimmune encephalomyelitis (EAE) mouse model. EAE is 
associated with neurodegenerative pathology, and a behavioral phenotype that is 
reflective of MS in humans, including the development of cutaneous mechanical and cold 
hypersensitivity (Olechowski et al. 2009, Rahn et al. 2014). We hypothesized that 
intrathecal administration of a CB2-selective agonist, JWH-133 (Huffman et al. 1999, 
Yamamoto et al. 2008), would decrease mechanical and cold hypersensitivity without 
locomotor side effects, and that this would be blocked by the CB2-selective antagonist, 
AM-630. 
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6.3  Materials and Methods 
6.3.1  EAE model 
 Our EAE model was designed with reagent concentrations that produce a mild-to-
moderate form of EAE, always yielding clinical scores of motor dysfunction below 3 and 4 
over the 4 week testing period (Rahn et al. 2014). All animals in the current study exhibited 
neither paresis of both hindlimbs nor paralysis of one hindlimb, thus   allowing nociceptive 
paw reflex testing. Briefly, myelin oligodendrocyte glycoprotein 35-55 (MOG33-55, 
AnaSpec Inc, Fremont, CA) was emulsified in a 1:1 solution of 1x PBS and complete 
Freund’s adjuvant (CFA).  To minimize the hyperalgesia produced by CFA itself, we 
reduced its concentration to 3 mg/ml. We used female C57BL/6 mice (Charles River), 
aged 12-14 weeks, housed 4 to a cage, habituated for 1 week in a temperature and 
humidity controlled environment on a 14/10-h light/dark cycle. Food and water were 
available ad libitum. Procedures were approved by the Institutional Animal Care and Use 
Committee of the University of Kentucky, protocol (#2010-0770). MOG was bilaterally 
injected (150 µg/100 µl s.c.) at the flanks under light isoflurane anesthesia on Days 0 and 
6. Pertussis toxin (List Biological Laboratories, Campbell, CA) was injected (200 ng/200 
µl, i.p.) on days 0 and 2 to facilitate opening of the blood brain barrier to T cells by 
histamine-induced vascular leakage and/or the priming of autoreactive T cells (Hofstetter 
et al. 2002). Control mice received CFA and pertussis toxin, but not MOG. Average weight 
of mice on week 4 was 21.8 ± 0.2 g. 
  
6.3.2  Intrathecal (i.t.) drug administration 
 Intrathecal injection was performed in lightly restrained unanesthetized mice as 
previously described (Fairbanks 2003). We injected 5 µl of drug [JWH-133 (Tocris, UK), 
AM-630 (Tocris, UK), or WIN55,212-2 (Cayman Chemical, Ann Arbor, MI) and/or vehicle 
[ethanol: alkamuls EL-620 (Rhodia, Cranbury, NJ): saline in a volume ratio of 1:1:8]. The 
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data of Figure 6-1 includes animals that were injected twice (Days 24 and 28 after the first 
MOG injection) using a balanced cross-over design. Animals receiving vehicle on day 24 
received drug on day 28, and vice versa. Group means of either vehicle or drug on day 24 
and day 28 did not differ, and so were combined for final analysis. The data of Figure 6-2 
were obtained on day 28 after two consecutive i.t. injections, separated by 15 min: first 
AM-630 or vehicle and then JWH-133, followed by behavioral testing sessions.  
 
6.3.3  Behavioral Testing 
 All animals were acclimated to a stainless steel grid within individual Plexiglas tubes 
for 30 to 60 min prior to behavioral testing. Somatosensory testing using mechanical (von 
Frey hair) and cold (plantar application of 5-8 μL acetone) stimuli was conducted as 
previously described (Solway et al. 2011). All experiments were conducted by a female 
investigator (W.F.), blinded to model and identity of drugs.  
 
6.3.4  Statistics  
 In Figs. 6-1A-B and 6-2A-B, differences between means were analyzed by two-way 
analysis of variance (ANOVA). Drug/Dose was a grouping factor and time was the 
repeated measure. If a significant interaction was found (p < 0.05), ANOVA was followed 
by post-hoc Bonferroni tests. Data were re-plotted as area under the curve, calculated 
using the trapezoidal method (Figs.6-1C-D and 6-2C-D). Effects of Drug were analyzed 
by one-way ANOVA followed by post-hoc Dunnett multiple comparison test. The best fit 
line for dose-response curves (Figs. 6-1E-F) was generated following non-linear 
regression analysis based on the 60 min post-injection thresholds. % Maximum Possible 
Effect (MPE) was calculated as:  
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𝑀𝑃𝐸 = 𝑝𝑟𝑒𝑖𝑛𝑗𝑢𝑟𝑦 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 − 𝑝𝑟𝑒𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 
% 𝑀𝑃𝐸 =
(𝑝𝑜𝑠𝑡𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡ℎ𝑟𝑒ℎ𝑜𝑙𝑑 − 𝑝𝑟𝑒𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡ℎ𝑟𝑒ℎ𝑜𝑠𝑙𝑑)𝑋100
𝑀𝑃𝐸
 
All data are presented as mean ± SEM. ★p < 0.05 was considered statistically significant.  
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6.4  Results 
6.4.1  CB2 agonist JWH-133 reduced EAE hypersensitivity in a dose-dependent manner 
 We first tested the hypothesis that activation of spinal CB2 suppresses mechanical and 
cold hypersensitivity in EAE mice. As illustrated in Figs 6-1A-D, at doses based on 
previous analgesia studies in mice (Yamamoto et al. 2008, Katsuyama et al. 2010, Curto-
Reyes et al. 2011), JWH-133 dose-dependently reduced mechanical (6-1A, F4, 33= 32.5, p 
< 0.0001) and cold hypersensitivity (6-1B, F4, 33 = 2.8, p < 0.05). The anti-hyperalgesic 
effect of JWH-133 (100 µg) for mechanical and cold hypersensitivity peaked at 60 and 30 
min respectively, with restoration of thresholds to baseline levels (0.77 ± 0.08 g, p > 0.05 
vs baseline; 2.52 ± 0.05 s, p > 0.05 vs baseline, respectively) within 180 min. Area under 
the curve (AUC) analysis (0-180 min) illustrates the concentration-dependent actions of 
JWH-133 (6-1C-D, p < 0.01).  As illustrated in Figs. 6-1E-F, dose-response curves yielded 
EC50 values of 49.0 µg and 33.5 µg for the mechanical and cold modalities, respectively. 
As illustrated in Fig. 6-2, JWH-133 (100 µg) did not change rotarod latency (p > 0.05). 
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Figure 6-1. Intrathecal JWH-133 suppresses mechanical and cold 
hypersensitivity in a dose-dependent manner 
The CB2-selective agonist JWH-133 was intrathecally (i.t.) administered 24-28 d (4 wk) 
after induction of EAE in C57/B6 mice. Time course and area under the curve (AUC) 
analysis of mechanical (A,C) and cold (B,D) hypersensitivity after JWH-133. Dose-
response analysis of the data at 60 min for mechanical (E) and cold hypersensitivity (F), 
respectively. MPE: maximum possible effect. Parentheses refer to number of animals per 
group. †p < 0.05 50 µg vs vehicle; ‡p < 0.05 100 µg vs vehicle; ★p < 0.05 vs vehicle. 
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Figure 6-2. Intrathecal JWH-133 does not disrupt motor coordination 
To determine whether JWH-133 produces side effects such as ataxia, we evaluated 
performance on an accelerating rotarod. We used WIN55-212,2 (WIN), a mixed CB1 and 
CB2 agonist with known sedative properties, as a positive control. Non-EAE mice were 
directed to walk forward on a rotating bar (Economex, Columbus instruments, Columbus, 
OH, USA), set to accelerate at a constant rate, from 4 to 40 rpm over 5 min. Mice learn 
quickly to walk on the rotarod, reaching a plateau within several acceleration trials. 
Therefore, training sessions of 4 trials were carried out on each of the 2 days prior to drug 
testing, to achieve a pre-drug latency to fall of approximately 3 min. On the experimental 
day, a baseline response (average of 3 consecutive trials) was obtained followed by 
administration of JWH-133 (100 μg), WIN (10 μg) or vehicle. Post-drug testing conducted 
30-45 min after injection consisted of three consecutive trials, which were averaged for 
analysis. A: WIN decreased latency to fall, from 200 ± 18 s to 108 ± 13 s, while JWH-133 
did not produce a significant change. B: Data expressed as the ratio of post- to pre-drug 
baseline. Parentheses refer to number of animals per group. Values represent mean ± 
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SEM. ★p < 0.05 vs respective pre-drug baseline by Student’s paired t-test; †p < 0.05 vs 
vehicle, ‡p < 0.05 vs JWH-133 by Turkey post-hoc test 
6.4.2  CB2 antagonist AM-630 prevented the anti-hyperalgesic effects of JWH-133 
 To further evaluate CB2 as the target of JWH-133, we intrathecally administrated 100 
µg JWH-133 followed by the highly selective CB2 antagonist AM-630 (Ross et al. 1999) at 
intrathecal doses in the low µg range (Gadotti et al. 2013, Ikeda et al. 2013). We did not 
include an AM-630 alone control group because these doses do not change sensory 
thresholds (Ikeda et al. 2013, Desroches et al. 2014). AUC analysis illustrates that AM-
630 dose-dependently attenuated the inhibitory effects of 100 µg JWH-133 on mechanical 
(6-3 C, F2, 11 = 15.0, p < 0.001) and cold hypersensitivity (6-3 D, F2, 11 = 4.2, p < 0.05).  
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Figure 6-3. CB2 antagonist blocks the anti-hyperalgesic effects of JWH-133 
The CB2 antagonist AM-630 was i.t. administered 15 min prior to i.t. JWH-133 (100 µg). 
Time course and AUC analysis (0-60 min) indicate that AM-630 attenuated the anti-
hyperalgesic effects of JWH-133 on mechanical (A, C) and cold (B, D) responses. 
★different from vehicle. ★p < 0.05 vs vehicle. 
 
 
 
140 
 
 
6.5  Discussion 
CB2 is an emerging target for pain relief as suggested by clinical trials and data from 
animal models of chronic pain (Anand et al. 2009, Rahn et al. 2009, Burston et al. 2013). 
For example, CB2 mRNA or protein levels were up-regulated in the spinal cord after 
peripheral nerve injury in rat (Zhang et al. 2003, Walczak et al. 2005, Wotherspoon et al. 
2005).  Furthermore, intrathecal administration of CB2 selective agonists generally 
reduced hyperalgesia in rodent models of peripheral neuropathic pain (as reviewed in 
(Rahn et al. 2009), but see (Brownjohn et al. 2012)). These anti-hyperalgesic effects were 
abolished in CB2 knockout animals (Yamamoto et al. 2008) or by co-administration of a 
CB2 selective antagonist (Malan et al. 2003, Beltramo et al. 2006, Gadotti et al. 2013), 
advancing a spinal CB2 site of activation. The current results extend these findings to the 
EAE model of multiple sclerosis pain. We found that the CB2 agonist JWH-133 reduced 
mechanical and cold hypersensitivity in EAE mice in a dose-dependent manner. CB2 
deletion mutant mice exhibit more severe disease scores (Maresz et al. 2007), while 
chronic systemic administration of CB2 agonists ameliorated disease progression in EAE 
animals (Palazuelos et al. 2008, Kong et al. 2014); however, it is highly unlikely that a 
single injection of  the CB2 agonist JWH-133 could impact disease progression within the 
3 hr window of behavioral observation in the current study. Pre-treatment with the CB2 
antagonist, AM-630, reversed the anti-hyperalgesic effects of JWH-133, suggesting a 
contribution of spinal CB2 to pain control in the EAE model. Consistent with this conclusion, 
MOG35-55 increased CB2 mRNA and protein levels in the spinal cord of EAE animals 
(Palazuelos et al. 2008, Lou et al. 2011), and CB2-immunoreactivity is significantly up-
regulated at the lesion sites of post-mortem human spinal cord from patients with MS 
(Yiangou et al. 2006). Our results are consistent with the analgesic effects of oral 
cannabinoid-based medications in patients with spinal cord injury (Maurer et al. 1990, 
141 
 
 
Hagenbach et al. 2007) and of CB2 agonists in rodents with spinal cord injury (Ahmed et 
al. 2010, Hama et al. 2010). 
Previous studies in a mouse model of nerve injury reported that intrathecal 
administration of 31 µg of JWH-133 (approximately 1.5-2.0 mg/kg) reduced behavioral 
signs of peripheral neuropathic pain, suggesting a spinal site of action (Yamamoto et al. 
2008). Similarly, in the current study we found that intrathecal doses of up to 100 µg of 
JWH-133 reduced behavioral signs of central neuropathic pain. Although we did not 
attempt injection of an equivalent systemic dose of JWH-133 (4.5 mg/kg, based on our 
average mouse weight of 22g), previous studies in the CFA model of inflammatory pain 
or the brachial plexus avulsion model of peripheral neuropathic pain indicate that systemic 
doses at or exceeding 10 mg/kg for JWH-133 are required to exert anti-hyperalgesic 
effects (da Silva et al. 2011, Del Fabbro et al. 2012). Similarly, a 5 mg/kg i.p. dose of JWH-
133 failed to reduce pain thresholds in the second phase of the formalin model of ongoing 
inflammatory pain (Jafari et al. 2007).  These data support our conclusion that intrathecal 
injection of JWH-133 acts at spinal sites and does not diffuse out of the spinal cord at 
sufficient concentrations to exert its anti-hyperalgesic actions at peripheral CB2. Further 
supporting a spinal site of action, we found that intrathecal injection of a low dose (3 µg) 
of the CB2 antagonist AM-630 blocked the anti-hyperalgesic effects of intrathecal JWH-
133. This low dose is equivalent to 0.135 mg/kg (based on our average mouse weight of 
22g), which is much lower than the 3mg/kg i.p. dose of AM-630 that was used to block the 
effect of 10mg/kg JWH-133 (da Silva et al. 2011, Del Fabbro et al. 2012), and so is unlikely 
to produce systemic effects. However, we cannot entirely exclude a contribution of 
peripheral CB2 at the intrathecal doses of JWH-133 used in our study because JWH-133 
(1-10 mg/kg i.p.) reduced weight bearing in rat models of cisplatin-induced neuropathic 
pain and carrageenan-induced inflammatory pain (Elmes et al. 2005, Vera et al. 2013).  
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Our rotarod data indicate that WIN55-212,2 produces ataxia, consistent with previous 
reports in rodents (Malan et al. 2003), and a consensus that activation of central CB1 
causes psychotropic effects and therefore compromises the therapeutic efficacy of 
cannabinoids to reduce clinical chronic pain, including MS pain (Smith 2002, Rahn et al. 
2009). By contrast, we found that JWH-133 reduced hypersensitivity at doses that do not 
produce ataxia.  This is consistent with previous studies in other pain models indicating 
an absence of motor impairment or catalepsy following systemic injection of analgesic 20 
mg/kg doses JWH-133 (Xi et al. 2011). Although JWH-133 exhibits substantial selectivity 
(200 X) for CB2 over CB1 (Huffman et al. 1999), we cannot exclude a contribution of CB1 
receptors located in the DRG and spinal cord to its analgesic actions because we did not 
administer it in combination with a CB1 antagonist. Thus, our data suggest that selective 
targeting of spinal CB2 reduces behavioral signs of neuropathic pain in the EAE model 
without untoward side effects.  Taken together with an emerging literature indicating that 
inhibitory effects of CB2 activation on the immune system may reduce the progression of 
neuromuscular dysfunction in the EAE model (Palazuelos et al. 2008, Kong et al. 2014), 
we conclude that the targeting of central CB2 poses strong therapeutic potential for the 
treatment of both motor dysfunction and pain in MS patients.  
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APPENDIX 
Abbreviations  
6Bnz N⁶ - Benzoyladenosine- 3', 5'- cyclic monophosphate sodium salt 
8cpt 8-(4-Chlorophenylthio)-2'-O-methyladenosine 3',5'-cyclic monophos- 
phate sodium salt 
AC Adenylyl cyclase  
AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor  
ANOVA Analysis of variance 
Calb Calbindin 
Calr Calretinin 
cAMP 
CS 
Cyclic adenosine monophosphate 
Central sensitization 
CB2 Cannabinoid receptor subtype 2 
CFA Complete Freund’s Adjuvant 
CGRP Calcitonin-gene related peptide 
CNS Central nervous system 
CpxSx Common peroneal nerve transection, sural nerve transection 
CSF Cerebrospinal fluid 
DAPI 4',6-diamidino-2-phenylindole 
Dox Doxycycline hyclate 
DRG Dorsal root ganglia  
EAE Experimental autoimmune encephalomyelitis 
EGFP Enhanced green fluorescent protein 
Epac Exchange protein directly activated by cAMP 
GABA Gamma-Aminobutyric acid 
GAD Glutamate decarboxylase 
GDP Guanosine diphosphate 
GFAP Glial fibrillary acidic protein 
GPCR G-protein coupled receptor 
GTP Guanosine-5'-triphosphate 
IASP International Association for the Study of Pain 
144 
 
 
IB4 Isolectin B4 
i.pl. Intraplantar 
i.t. Intrathecal 
LS Latent senstitization 
LTP Long-term potentiation 
MAPK Mitogen-activated protein kinases 
MOG Myelin oligodendrocyte glycoprotein 
MOR Mu-opioid receptor 
MPE Maximum possible effect 
MS Multiple sclerosis 
NeuN Neuronal nuclei 
NK1/NK1R neurokinin 1 receptor 
NMDAR N-methyl-D-aspartate receptor 
nNOS Neuronal nitric oxide synthases 
NPY Neuropeptide tyrosine 
Ox-42 Integrin alpha M 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PKA Protein kinase A 
PKC Protein kinase C 
Sac Saccharin  
SNI Spared nerve injury 
SP Substance P 
SST Somatostatin  
TRPA1 Transient Receptor Potential cation channel A1 
TRPV1 Transient Receptor Potential cation channel V1 
VGLUT1 Vesicular glutamate transporter 1 
VGLUT2 Vesicular glutamate transporter 2 
VGLUT3 Vesicular glutamate transporter 3 
Y1R Neuropeptide tyrosine receptor 1 
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